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Abstract 
 
Chemical and biological threats are ever present and attacks have occurred throughout the 
world in both war and peace-time.  Multiple government agencies, academia, and private 
industry are developing detection capabilities to address such threats.  The research 
presented in this paper supports development of a modular synthetic biology-based 
system that detects and reports the presence of a threat agent.  Synthetic biology builds 
upon past research in genetic engineering and seeks to combine broad applications within 
biotechnology in novel ways.  This basic research project will help to demonstrate a 
proof-of-concept design which will guide future studies on the development of a modular 
sensor platform.  In this study, in vitro and in vivo techniques were used to evaluate a 
reporter system composed of the Tobacco Etch Virus (TEV) protease and an engineered 
fluorescent fusion protein for their combined effectiveness as a reporter system.  The 
TEV protease demonstrated the ability to cleave the fusion protein construct to produce a 
measureable output signal.  The coupling of this reporter system with a riboswitch 
recognition element showed that this modular system can be applied to detecting 
chemicals.  Further studies to modify this recognition element suggest modularity for 
future biosensors to detect chemicals of military interest.  
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CHARACTERIZATION OF TOBACCO ETCH VIRUS PROTEASE AND 
FLUORESCENT FUSION PROTEINS IN A REPORTER PATHWAY 
 
 
 
I. Introduction 
 
 
Overview 
 This thesis addresses a growing need for early detection and reporting of 
biological and chemical agents that adversely affect the warfighter.  This chapter 
provides a context to familiarize the reader with current and relevant technical 
background and procedures.  The chapter starts with the background of a threat to the 
warfighter, discussion of synthetic biology, and the top-level research design of this 
thesis. The remaining sections discuss the problem statement, research objective with 
investigative questions, thesis methodology, and assumptions and limitations. 
Background 
Chemical and biological threats are ever present and attacks have occurred 
throughout the world in both war and peace-time.  Military and civilian populations are 
under an increased threat from biological and chemical agents from terrorists and 
extremists.  In March 1995, the Aun Shinrikyo cult unsuccessfully attempted to deploy 
botulinum toxin in a Japanese subway station, but succeeded in a second attack at several 
of the Tokyo subway lines with sarin gas, resulting in 12 deaths and many more were 
wounded (Center for Disease Control, 1995).  In 2001, anthrax spores were mailed to 
several Unites States (US) media centers and two US senators.  These domestic terrorist 
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actions resulted in five deaths and many individuals infections (Federal Bureau of 
Investigation, 2001).  In order to prevent or deter future events, adequate detection 
systems are necessary to identify the presence of biological and chemical threat agents.   
Multiple government agencies, academia, and private industry are developing 
threat detection capabilities.  According to the 2006 Quadrennial Defense Review (QDR) 
Report, “the Department [of Defense] has nearly doubled its investments in chemical and 
biological defenses since the 2001 QDR” (Department of Defense, 2006).  The Defense 
Threat Reduction Agency (DTRA) contracted with the National Research Council to 
examine “detect to warn” biological sensors for facilities protection (National Research 
Council, 2004).  Within the Department of Defense, the Office of Naval Research, Army 
Research Laboratories, and Air Force Research Laboratory (AFRL) have departments 
focusing on biological and chemical detection methods.   
Research includes development of computer-based, mechanical, and biological 
systems.  Dr. Stuart Rubin, from the Space and Naval Warfare Center (SPAWAR), has 
developed an anthrax sensor based on a computer program called Knowledge 
Amplification by Structured Expert Randomization.  This sensor can be modified to 
detect improvised explosive device (IED)-associated chemicals.  Drs. Pamela Boss and 
Richard Waters of SPAWAR are developing sensors that use micro-electrical mechanical 
system devices that have the ability to detect multiple chemical and biological agents 
(Ceruti, 2007).   
In addition to examining biological sensors, DTRA is evaluating nanotechnology 
for applications in detection.  Nano-materials are very small, ranging from 1 to 1000 
billionths of a meter in size, and behave differently than materials at the macro level 
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(Peck, 2007).  One advantage of nanotechnology is its small size: a higher quantity of 
engineered nano-detectors will fit on a small surface area.  These detectors will be able to 
detect minute concentrations of the hazard agent, making them much more sensitive than 
many detectors available today.  Research in nanotechnology is adding to both biological 
and chemical agent detection.  Figure 1 provides a relative scale of nano and biological 
constructs. 
 
Figure : Relative Scale for Nano and Biological Constructs 
(Adapted from Frasier, 2005) 
 
Advancements in the relatively new field of synthetic biology include applications 
of nano- and biotechnology.  The field has matured to the point where the power and 
flexibility of biology can be harnessed to develop novel threat detection solutions.  As the 
focus of this thesis utilizes the discipline of synthetic biology, it is addressed in greater 
detail below. 
     Synthetic Biology 
Synthetic biology refers to engineered biological systems, or systems manipulated 
by man in order to construct materials, produce energy, maintain or enhance human 
health, and process chemicals.  It builds upon past research in genetic engineering and 
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seeks to combine broad applications within biotechnology, with an emphasis on 
developing technologies to improve the design and development of biological systems 
(Endy, 2005).  It is a revolutionary science with great potential to impact society, 
medicine, and military technology. 
Synthetic biology follows a strategy of constructing simplified systems in order to 
understand or manipulate cellular regulatory processes (Simpson, 2006).  Typical cellular 
functions involve retrieving information from deoxyribonucleic acid (DNA), transcribing 
and translating the information from these genes to synthesize protein, regulating energy 
metabolism and repair, as well as cellular replication.  One method of simplifying such 
functions is to use cell-free strategies that do not require the entire cellular system.  For 
example, cell-free strategies that replace complex cellular processes with purified 
enzymes perform limited functions of natural cellular activities (Shimizu et al., 2001).  
The use of these cell-free strategies minimizes unintended interactions by removing 
biochemical reactions which support synthetic gene pathways (Simpson, 2006).   
     Research Design 
The Human Effectiveness (RH) directorate at AFRL is conducting related 
research within the Applied Biotechnology Branch.  Within the branch, the Cellular 
Development and Engineering Program has been tasked to develop a modular synthetic 
biology-based system that detects and reports the presence of a threat agent.  The 
research is categorized as basic research, resulting in proof-of-concept demonstration.  
This proof-of-concept research focuses on developing a system which demonstrates 
detection of a small molecule through the reporting activity within the synthetic system.   
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The synthetic system is composed of numerous biochemical reactions.  An 
overview of the synthetic system evaluated in this paper is provided in Figure 2.  The 
biochemical pathways are initiated with the binding of a small molecule to a catalytic 
ribonucleic acid molecule (RNA), called a ribozyme (Thodima et al., 2006).  The 
ribozyme is part of a larger RNA construct, called a riboswitch, which initiates 
translation of a specific genetic sequence on a plasmid (circular DNA molecule).  The 
gene product in this research design is an enzyme which cleaves a fluorescent protein, 
resulting in an optical output.  The enzyme and fluorescent protein constitute the reporter 
system.  Initial research involved evaluation of the reporter system in cell-free 
environment using a buffer system and an in vitro translation/transcription system with 
purified enzymes.  Additional studies were accomplished in vivo to optimize cellular 
machinery.   
 
Figure : Research Design Flow Chart  
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A future phase of the research plan identifies encapsulation of the synthetic 
system in order to stabilize and transport the system for use in the field.  Many of these 
steps are being investigated in parallel, a factor that increases the design complexity if 
some of the biomolecules do not demonstrate the anticipated results. 
Problem Statement 
This thesis characterizes the reporting activity of an enzyme-substrate reaction in 
the synthetic system.  The experimental design used Tobacco Etch Virus (TEV) protease 
(enzyme) because of its high specificity to cleave engineered fusion proteins (substrate) 
containing the TEV protease amino acid linker.  Proteases are a class of enzymes that 
catalyze the cleavage of specific peptide bonds in proteins (Medintz et al.; 2006; Zhang, 
2004).  Fusion proteins are single protein molecules genetically engineered from two 
separate protein molecules and linked by a peptide sequence of amino acids.  For this 
research, the fusion protein was engineered to include the specific peptide sequence 
recognized by the TEV protease.  The engineered fusion proteins demonstrated different 
levels of fluorescence at specific wavelengths when whole and cleaved, enabling 
detection of TEV protease activity.  Details regarding TEV protease and the fluorescent 
fusion protein are addressed in Chapter II: Literature Review. 
The problem statement is best described as how to characterize the protease and 
fluorescent fusion protein interactions in the synthetic system to accurately report the 
presence of a molecule of interest.  Characterization is a critical aspect of the research, 
because other steps in the research design might introduce factors that affect either the 
proteases activity or interfere with the fusion protein fluorescence properties.  Additional 
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considerations, such as enzyme reaction time and enzyme/protein concentration, affect 
optimization.  These factors are addressed in more detail in the following sections. 
Research Objective/Questions 
The objective of this thesis is to characterize TEV protease interactions with a 
fluorescent fusion protein in order to support the larger research design of a reporter 
system.  To attain the objective, several investigative questions need to be answered: 
1. Does the TEV protease and fluorescent fusion protein interaction result in a robust 
output signal? 
2. How will enzyme-substrate interaction behave in different systems?  
a. A simple Buffer System, in vitro transcription translation system, and in vivo 
system 
b. What is the time factor for the earliest distinguishable output signal? 
3. Will introduction of a sensing element (riboswitch) negatively affect the downstream 
reporter system and output signal?  
Methodology and Data Analysis 
 This thesis research was based on laboratory analysis of TEV protease and 
fluorescent fusion proteins.  Routine techniques followed published protocols and 
deviations were documented.  Published research papers identified alternative techniques 
or protocols.  Initial experiments were performed as a demonstration of activity, followed 
by verification that the correct activity occurred.  Due to the nature of the multiple 
demonstration and verification cycles, data for statistical analysis was limited.   
 In vitro and in vivo experiments were conducted to evaluate the enzyme’s ability 
to cleave fluorescent protein.  Figure 3 represents the biochemical pathway and 
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associated analyses performed at each stage.  Gene sequencing confirmed the source 
DNA.  Spectroscopy and gel electrophoresis quantified messenger RNA (mRNA) purity 
and concentration.  Complementary DNA (cDNA) was derived from mRNA and 
evaluated by real-time polymerase chain reaction (qPCR).  Polyacrylamide gel 
electrophoresis and high performance liquid chromatography (HPLC) verified the 
reaction protein products.  Fluorescent spectroscopy evaluated the cell constituents of the 
reaction products.   
 
Figure : Biochemical Pathway and Analyses for Experimental Design  
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test and Analysis of Variation (ANOVA) to determine if results were statistically 
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for transportability, specificity for specific analytes, and reaction and reporting time.  The 
proof-of-concept design would need to expand evaluation of multiple hazards to address 
detection of IEDs, biological agent, or chemical compounds.  
One limitation of the thesis was the low number of replications for each 
experiment.  In vitro experiments were used to provide insight for later in vivo analysis of 
the reporter system.  In vivo experiments using bacterial cell cultures were repeated using 
different experimental conditions and required greater time and personnel commitments, 
so statistical analysis of the data was also limited by a small number of replications.  Due 
to the time limit placed on AFRL/RH to demonstrate the proof-of-concept, concurrent 
research among multiple scientists was required to develop optimal protocols and 
investigate the research design under different conditions.   
 
 
 10 
 
II. Literature Review 
 
 
Chapter Overview 
 In an effort to develop a modular sensing platform that identifies molecules that 
could pose a threat to humans or the environment, scientists have applied synthetic 
biology techniques to develop sensing and reporter systems.  These sensing systems are 
engineered to detect an analyte or small molecule agent which, through a series of gene 
expression and downstream interactions, results in a signal that reports the analyte 
presence (the reporter pathway).  Detection might be expressed through optical, chemical, 
or electrical output from the system. 
 Programs at the Air Force Research Laboratory are evaluating these types of 
systems.  The development of the sensor and reporter system requires numerous steps.  
This thesis evaluated the optical reporter system based on the interactions of the Tobacco 
Etch Virus (TEV) protease with an engineered fluorescent protein construct in both in 
vitro and in vivo environments.  The in vivo evaluation included insertion of the sensor 
element, the riboswitch, upstream of the TEV protease gene to determine down-stream 
signal efficiency.  In this chapter, previous research on riboswitches, TEV protease, 
fluorescent proteins, and general concepts of Fluorescence Resonance Energy Transfer 
(FRET) are addressed.  In addition, a review is provided on the molecular biology 
techniques used throughout this evaluation.   
Riboswitches 
 Riboswitches were used in the experimental design as a small molecule sensing 
mechanism that moderates the TEV protease expression at the translation level.  This 
 11 
section defines the riboswitch, describes a proposed mechanism of action, and addresses 
some limitations and benefits from riboswitch research performed to date. 
Riboswitches are small segments of messenger RNA (mRNA) that function as 
genetic “on” or “off” switches in the presence of a small molecule ligand (Lynch et al, 
2007; Desai & Gallivan, 2004).  They are composed of two domains: an aptamer domain 
which recognizes a metabolite or small molecule ligand, and an expression platform 
which is a secondary structure formed upon ligand-binding that directly controls gene 
expression at the transcriptional or translational level (Stoddard & Batey, 2006; Lynch et 
al., 2007; and Buck et al., 2007).  The riboswitch consists of non-coding elements located 
in the 5’ untranslated region upstream of regulated genes in prokaryotic and some 
eukaryotic mRNA (Buck et al., 2007; Lynch et al., 2007; and Barrick et al., 2004).  
Because of the potential applications for riboswitches as genetic screens for small 
molecules, much research has focused on development of synthetic riboswitches that can 
be adapted to selectively recognize small molecules and metabolites (Barrick et al., 2004; 
Desai & Gallivan, 2004; Bayer & Smolke, 2005; Gilbert & Batey, 2005; and Lynch et al., 
2007). 
 The riboswitch gene expression is thought to be modulated through allosteric 
conformational changes affected by ligand-binding to the aptamer domain (Buck et al., 
2007; Sashital & Butcher, 2006; and Barrick et al., 2004).  The aptamer domains can 
adopt complex structures that precisely recognize the ligand with high binding specificity 
and a greater affinity than the non-ligand-bound state, resulting in a structural 
rearrangement in the mRNA tertiary structure (Barrick et al., 2004; Sashital & Butcher, 
2006; and Lynch et al., 2007).   
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Lynch et al. (2007) proposed potential mechanisms of action of synthetic 
riboswitches with their research on the theophylline-sensitive riboswitch in Escherichia 
coli, illustrated in Figure 4.  In the absence of the theophylline ligand, hydrogen bonding 
and electric static forces pair the aptamer sequence (ligand binding site) with the 
ribosome binding site (RBS).  The structure bonds the Start AUG codon to 
complementary nucleic acids and prevents initiation of mRNA translation.  Addition of 
theophylline causes a conformational change in the secondary structure as the aptamer 
binding site forms a pocket for the ligand and complementary base-pairing shifts, thus 
liberating the RBS and Start codon sites.  Because the 30S subunit of the ribosome binds 
most efficiently to the single-stranded regions of RNA, translation of the downstream 
gene can be initiated.  The theophylline-bound state was determined to be 
thermodynamically favorable over the ligand-free state through free energy calculations.   
 
Figure : Predicted Mechanisms of Action of Synthetic Riboswitches 
 (Lynch et al., 2007) 
 
In 2007, Lynch et al. reported that the theophylline-sensitive riboswitch did not 
completely repress protein translation in the absence of theophylline, resulting in 
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background noise.  They postulated that, in the absence of the ligand, the RBS is paired 
such that transcription is minimized.  Their research reported that the most effective 
riboswitch showed a signal to background ratio of approximately 8, and that an increase 
in that ratio is desirable for more demanding screening applications.  Buck et al. (2007) 
also reported low levels of protein expression in the ligand-free state, suggesting that the 
base-pairing interactions “are not sufficient to completely lock the positions of helices in 
a defined orientation,” whereas the ligand-bound state tightens the complex and decreases 
fluctuations. 
Even though the structural conformity of synthetic riboswitches is not static in the 
ligand-bound and unbound states, riboswitches offer flexible control strategies as small 
molecule sensors due to their design variability as genetic regulators.  A range of 
riboswitch designs have been cataloged over the last few years.  Research performed by 
Desai & Gallivan (2004), Lynch et a.l (2007), and Buck et al. (2007) report on synthetic 
riboswitches in which the bound ligand turns “on” gene expression, while research by 
Sashital & Butcher (2006) and Barrick et al. (2004) describe riboswitch designs in which 
the bound ligand turns “off” gene expression.   
These studies indicate small molecule specificity to the aptamer section of the 
riboswitch, further enhancing their significance as discriminating sensors.  Topp & 
Gallivan (2007) report that caffeine, a small molecule differing from theophylline only by 
a methyl group at the N7 position, does not bind to the riboswitch (refer to Figure 5). 
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Figure : Theophylline and Caffeine Molecules 
 
Anderson & Mecozzi (2005) demonstrated through computational modeling and 
experimental observations that an RNA sequence as short as 13-nucleotides can 
selectively bind to theophylline.  According to Lynch et al. (2007), “synthetic 
riboswitches can be engineered to respond to any non-toxic cell-permeable molecule that 
is capable of interacting with RNA.”   
Tobacco Etch Virus Protease 
 The Tobacco Etch Virus (TEV) protease was chosen for use in the experimental 
design of this thesis for its well-characterized specificity and its ability to operate in a 
wide range of conditions.  This section describes the physical nature of the TEV protease, 
the properties that make it desirable for cleaving fusion proteins, and the research 
accomplished to improve limitations of the TEV protease found in nature. 
TEV protease is an efficient, highly specific enzyme, categorized as a nuclear 
inclusion a (NIa) protease, with a unit mass of 27 kilo Daltons (kDa) (Fang et al., 2007; 
Nunn et al., 2005).  The NIa protease recognizes a standard amino acid sequence 
recognition site: Glu-X-X-Tyr-X-Gln|Gly, where X represents any residue and Gln|Gly 
represents the protein cleavage site (Fang et al., 2007; Nayak et al., 2003).  Parks et al. 
(1994) indicate that cleavage is also successful with a Gln|Ser mutation.  Because the 
TEV protease recognition sequence can be cloned between fusion proteins, its seven 
Theophylline Caffeine 
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amino acid standard recognition site makes it valuable when cleaving genetically 
engineered fusion proteins (Kapust et al., 2001).  The short, highly specific cleavage site 
can be inserted between proteins not found in nature.  TEV protease is active over a 
temperature range from 4oC to 37oC and a pH range from pH 6.0 to pH 8.5 (Nayak et al., 
2003; Fang et al., 2007).  
For purification and identification, a 6x polyhistidine (His)-tag can be attached to 
the carbon (C) or nitrogen (N)-terminus of the protease (Nayak et al., 2003).  Purification 
is normally required after in vivo protein expression.  Cells are lysed (broken apart) to 
separate the cellular components from the cytoplasm.  Cell lysates contains many types of 
proteins, the His-tag enables single step purification through Nickel (Ni2+) affinity 
chromatography (Fang et al., 2007).   
Using Ni-nitrolacetic acid (NTA) beads, the cell lysate equilibrates with the 
column beads, allowing the protein with the His-tag to bind to the Ni-NTA column.  The 
column is then washed with buffer containing low concentrations of phosphate and 
imidazole to elute out other cell lysate proteins that have low affinities for the Ni2+ in the 
column.  Imidizole will affect the pH of the buffer, and also has a higher affinity for 
nickel.  Addition of an imidazole and high salt solution results in target protein elution 
from the Ni-NTA column (Wallert & Provost Lab, 2004; QIAGEN, 2008).  The His-tag 
provides a means to identify the protein in a complex mixture using immunoblotting with 
an antibody to the His-tag (Western Blot).  Figure 6 depicts one variation of TEV 
protease, mutant S219D, with its catalytic domain and His-tag. 
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Figure : Ribbon Model of the TEV(S219D) Protease Structure 
The residues that compose the catalytic triad and the N-terminal 
His tag are depicted as ball-and-stick models (carbon, violet; 
nitrogen, blue; oxygen, red; and sulfur, yellow). The peptide 
product is also colored blue to distinguish it from the protein (Phan 
et al., 2002). 
 
Fang et al., 2007, reported an improved strategy for high level yield of soluble 
TEV protease in E. coli through the use of molecular chaperones and lower culturing 
temperatures.  The molecular chaperones E. coli GroES/EL and trigger factor promoted 
correct protein folding and inhibited incorrect hydrophobic interactions of peptides 
during translation.  The lower temperature appeared to reduce folding errors by slowing 
the translation speed.  Both factors were shown to contribute to a high yield of soluble 
TEV protease. 
The wild-type TEV protease is limited by its low stability which results in auto-
digestion.  It cleaves itself at a specific site resulting in a truncated protease which 
exhibits reduced activity, reduced enzyme purification product, and longer processing 
time to separate the truncated and full-length protease (Kapust et al., 2001).  Kapust et al. 
(2001) identified that S219V mutant was impervious to autolysis while maintaining its 
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catalytic activity, whereas Lucast et al. (2001) identified that the S219N mutant inhibited 
auto-proteolysis and subsequent inactivation.   
Another limitation of the wild-type TEV protease, when expressed in Escherichia 
coli, (E. coli) is its low solubility.  Van den Berg et al. (2006) performed directed 
evolution studies and identified the S219N mutant of TEV protease as demonstrating 
increased solubility.  After analysis of several mutants through purification and activity 
testing, one mutant, designated as TEVSH, was selected as the top performer due to its 
five-fold increase in yield after purification.  The substitutions at T17S, N68D, and I77V 
on TEVSH improved solubility and retained proteolytic activity.   
In 2007, Fang et al. noted that the cleavage efficiency of TEV protease was more 
dependent upon the substrate than the enzyme itself.  The protease efficiency was 
affected by the substrate’s conformal structure and accessibility to the cleavage site; 
however, comparative studies on TEV protease efficiency with different types of 
substrates are still being evaluated (Kapust, 2001).  Further analysis may be required to 
identify an enzyme-substrate combination that maximizes cleavage efficiency when 
designing an optimal reporting system.   
 For this reporter system design, both an enzyme and substrate are required.  The 
TEVSH protease variant was selected for this research because it demonstrated stability, 
solubility, and high yield in E. coli.  The selected substrate must incorporate the TEV 
protease recognition sequence and display good optical characteristics, which are 
discussed in the next section.   
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Fluorescent Proteins, FRET, and FRET Pairs 
To be effective as a reporter system, the activity of the optical assay must 
discretely measurable.  The optical signal verifies the TEV protease activity as well as 
activation of the riboswitch.  This section describes the fluorescent protein engineered 
with the TEV protease linker, the fluorescence resonance energy transfer (FRET) 
phenomenon that enhances its optical significance and an analysis of different FRET 
pairs. 
     Fluorescent Proteins 
Green fluorescent protein (GFP) is a fluorescing molecule, called a fluorophore, 
widely used in synthetic biology for their chromophoric (color-changing) properties.  
GFP has become well established as a marker in gene expression and protein targeting for 
in vitro and in vivo studies (Tsien, 1998).  Low amounts of soluble GFP can be detected 
in a reaction mixture and fluorescence intensity correlates with concentration of soluble 
protein (van den Berg et al., 2006).  GFP has five classes of mutants that have been 
studied in cellular biology: enhanced GFP (eGFP); blue fluorescent protein (BFP), cyan 
fluorescent protein (CFP), yellow fluorescent protein (YFP), and sapphire fluorescent 
protein (Pollok & Heim, 1999).  The fluorophores are excited, or absorb energy, at one 
wavelength and emit energy, fluorescence or brightness, at a different wavelength (Pollok 
& Heim, 1999).  These values are necessary when evaluating their presence in a 
biological system.  Figure 7 illustrates the different excitation and emission spectra for 
different GFP mutants. 
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Figure : Relative Excitation and Emission Spectra for GFP Mutant Classes  
(Pollok & Heim, 1999). 
 
     FRET 
Fluorescence Resonance Energy Transfer (FRET) has been used in cell biology to 
analyze gene expression, monitor protein folding, and design fluorescence sensor 
molecules (Pollok & Heim, 1999; Mitra et al., 1996; and Kikuchi et al., 2004).  Some 
literature has also referred to FRET as Förster resonance energy transfer, due to the 
Förster equation which describes the rate at which energy is transferred from donor to 
acceptor (Mitra et al., 1996).  
FRET is a quantum-mechanical phenomenon demonstrated in this study by the 
fluorescent fusion protein.  The event occurs when two fluorophores are excited and the 
donor fluorophore transfers energy to an acceptor fluorophore (Mitra et al., 1996; Pollok 
& Heim, 1999; and Zhang, 2004).  These fluorophores must be in close proximity (10-
100 Å) and the emission spectra of the donor must overlap with the excitation of the 
acceptor fluorophore (Mitra et al., 1996; Eggeling et al., 2005; and Zhang et al., 2002).  
Because energy is transferred without emission of a photon, FRET is considered a non-
radiative process (Kikuchi et al., 2004), as illustrated in Figure 8 .   
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Figure : Detection Principle of FRET Sensor 
D represents donor; a represents acceptor; 
cleavage of bond represented by hydrolysis or 
enzyme (Kikuchi et al., 2004) 
 
One benefit of FRET is that it enables a ratiometric measurement in which a ratio 
calculation is obtained from simultaneous recording of the fluorescent intensities at two 
wavelengths (Kikuchi et al., 2004).  This technique provides greater precision and is 
preferable to a single wavelength measurement or fluorescent intensity measurement 
(Kikuchi et al., 2004; Zhang et al., 2002). 
     FRET Pairs 
FRET pairs are used to enhance detection and monitoring of target proteins, 
protease activity, and effects of protease inhibitors in real-time and in living cells (Mitra 
et al., 1996; Zhang, 2004).  Several types of FRET pairs exist, such as pairs with protein-
protein interactions, a conformational change region, intra-molecular interactions in the 
linker region, and fusion proteins (Zhang et al., 2002).  FRET-based fusion proteins are 
the result of recombinant DNA in which two DNA fragments that code for different 
proteins are ligated together to code for a single protein (Sindelar & Crommelin (ed), 
2002).  In experimental studies supporting this thesis, a FRET-based fusion protein was 
constructed as the substrate to monitor TEV protease activity. 
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The FRET fusion protein is linked by an amino acid sequence that can be 
recognized and cleaved by an enzyme of interest.  Some common FRET pair 
combinations are BFP-eGFP and CFP-YFP (Pollok & Heim, 1999).  In a FRET pair 
naming convention, the first fluorophore is the donor and the second fluorophore is the 
acceptor.  If the fusion protein has been engineered with a peptide linker for enzyme 
cleavage, the enzyme name is inserted between the proteins.  For example, 
BFPTEVEGFPHis indicates the BFP-EGFP fusion protein is cleaved by a TEV enzyme.  
The His-tag at the end of the fusion protein is used during purification as well as a tool 
for identification. 
The FRET pair selection is dependent upon several factors: overlapping excitation 
and emission spectra, wavelength distance between emission spectra to be able to 
distinguish between fluorophores, orientation, and physical distance between the 
fluorophores (Eggeling et al., 2005).  In addition to selection of appropriate fluorophores, 
the length of the polypeptide linker should be optimized to ensure the spatial distance 
required for FRET is not compromised (Zhang et al., 2002; Zhang, 2004).  The amplitude 
of the in vitro FRET signal may be affected by factors such as salt concentration, buffer 
composition, reducing agents, and mineral concentration (Dong et al., 2004). 
The first demonstration of FRET between two GFP derivatives was accomplished 
by Mitra et al. in 1996, using BFP-red shifted GFP.  Zhang et al. (2002) reference other 
applications that have used BFP-GFP; however, results indicated dimness and BFP 
experienced photo-bleaching – an irreversible destruction of a fluorophores being 
illuminated (Zhang et al., 2002).  Research by Zhang in 2004 reported that cleavage of 
the CFP-YFP fusion protein by thrombin demonstrated an increased emission ratio and 
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concluded that the pair was a better candidate for design of FRET-based GFP probes than 
BFP and GFP fluorophores.  Though Zhang’s experimental design tested the FRET probe 
by thrombin cleavage, the results indicate the CFP-YFP pair is worth investigating in the 
experimental design.  
This section addressed the use of fluorescent molecules as a fusion protein.  The 
construct and cleavage of the fusion protein demonstrate FRET, an optical property 
which can be measured to determine enzyme activity.   
Techniques 
     Polyacrylamide Gel Electrophoresis 
Polyacrylamide gels are formed from the polymerization of acrylamide, creating a 
matrix which aids in separating proteins based on size.  The size of the protein(s) to be 
separated dictates the percent acrylamide in the gel to be used.  The smaller the protein, 
the larger the percent acrylamide in the gel required.  For example, 10% acrylamide gels 
are recommended for proteins ranging from 21 to 100 kDa in size, whereas 12% 
acrylamide gels are recommended for proteins ranging from 10 to 40 kDa.  
Electrophoresis is the movement of charge molecules in an electric field.  Either non-
denaturing or denaturing polyacrylamide gel electrophoresis can be used to extract 
information about the protein of interest.   
Non-denaturing gels, also called native gels, are used to determine whole protein 
size and charge.  Most proteins have an inherent electrical charge.  Electrophoresis 
provides the electrical gradient which transports charged protein through the gel while the 
acrylamide provides the molecular sieving.  Larger proteins migrate more slowly and are 
observed closer to gel wells (Boyer, 1993). 
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Denaturing gels, also known as SDS-PAGE, are used to determine the molecular 
mass of proteins.  Proteins samples are treated so they have a uniform charge by using a 
detergent, sodium dodecyl sulfate (SDS), and 2-mercaptoethanol (β-ME), a disulfide 
reducing agent.  These SDS denatures the proteins secondary, tertiary, and quarternary 
structure to produce a linear polypeptide chain coated with negatively charged SDS 
molecules.  The β-ME assists in protein denaturation by reducing disulfide bonds.  The 
bound SDS molecules mask the native charge of the protein, allowing the protein to 
move though the polyacrylamide gel based soley on size when electrophotesed.  Like 
non-denaturing gels, larger molecules migrate slower and are found near the top of the 
gel (Boyer, 1993). 
     Agarose Gel Electrophoresis 
Agarose gels are used primarily for analyzing DNA or RNA because of the pore 
size of the agarose medium allows movement of lager nucleic acid fragments or intact 
DNA molecules (up to 50 kilobases (kb) or 1850 kDa in terms of protein).  DNA is 
measured by kb, whereas proteins are measured in terms of kDa, with a conversion of 1 
kb = 37 kDa.  Agarose is a product extracted from seaweed and sold in powder form.  
The powder is dissolved in warm eletrophoretic buffer, and prior to cooling, ethidium 
bromide is added.  The ethidium bromide intercolates between nucleic acid bases and the 
RNA or DNA fluoresces when illuminated with ultraviolet light.  Similar to 
polyacrylamide gels, the molecular size and conformation of the nucleic acid should 
determine the percent agarose in the gel.  Smaller, compact and supercoiled molecules 
move faster when an electrical current is applied.   
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     Polymerase Chain Reaction (PCR) 
In this experimental design, polymerase chain reaction (PCR) was used as a 
method to assist in plasmid construction as well as analysis of the experimental products.  
PCR is a technique that amplifies a small amount of DNA without the use of cloning 
techniques.  Developed by Kary Mullis in the 1980’s, PCR has been widely used in 
molecular biology because it requires only a small sample of DNA, it amplifies a specific 
sequence of interest, and it helps to facilitate site specific mutagenesis using primers to 
amplify a changed sequence.  It has been found useful for DNA diagnostics to check for 
the presence of a gene, check mutation states of genes, and amplify a specific DNA 
sequence in a population of mixed DNA (Moran et al., 1994; Griffiths et al., 1999).  PCR 
can be used to verify the previous experimental results by blotting or sequencing the PCR 
products, or can be used for additional experimentation by cloning the PCR product into 
other DNA sequences. 
 With PCR, sequenced information from double stranded DNA is used to design 
primers that flank the region to be amplified.  These primers are complementary to the 
opposite strand with their 3’ ends oriented toward each other.  The reaction mixture 
contains the source DNA, excess primers, DNA polymerase, oligonucleotides, and a 
buffer solution. 
Polymerase chain reaction is broken down into three steps per cycle: denaturation, 
annealing, and elongation.  The time and temperature in each step varies, and is primarily 
dependent on the melting point of the DNA primer.  A temperature and time range is 
described below for each step; however, protocols will specify optimal conditions that 
should be followed.  The source DNA is denatured by heating the reaction mixture at 94-
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98°C for 10 to 30 seconds, disrupting hydrogen bonds between bases to yield single 
stranded DNA.  Upon cooling to 50 to 65°C for 20 to 60 seconds, the primers 
preferentially anneal to their complementary sites, which border the DNA sequence of 
interest.  Elongation proceeds when a temperature-resistant DNA polymerase, commonly 
Taq polymerase, catalyzes growth in the 5’ to 3’ direction from the DNA primers using 
available oligonucleotides.  Elongation process occurs at 72-80°C and lasts for one 
minute.  At the end of the first cycle, the quantity of initial double-stranded DNA has 
doubled.  After the second cycle, the DNA has again doubled.  Each cycle result in an 
exponential increase in the number of DNA segments replicated.  These cycles are 
repeated from 20 to 35 times, depending on the application, until the desired DNA 
constitutes virtually all the DNA (Moran et al., 1994; Griffiths et al., 1999; McPherson & 
Moller, 2006). 
Many variations of the basic PCR procedures have been developed to aid in 
biomolecular analysis.  Some examples include reverse transcription PRC (RT-PCR) 
which amplifies RNA, and real-time PCR (qPCR), which quantifies DNA or RNA by 
measuring the accumulation of DNA product after each round of PCR amplification. 
     Plasmid Construction 
In order to express TEV protease or BFPTEVeGFP protein in a cellular 
environment, recombinant DNA techniques were used.  These techniques insert a specific 
DNA code into a plasmid vector which will express the protein when transcription and 
translation are initiated.  This section provides a generic description of a plasmid and 
recombinant DNA techniques used to clone foreign DNA into a plasmid.   
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 A plasmid is an independently replicating circular double stranded DNA molecule 
(Moran & Scrimgeour, 1994).  It carries genes for the inactivation of antibiotics in 
addition to hosting foreign DNA strands (Figure 9).  The origin of replication refers to the 
site where the entire plasmid DNA is replicated during DNA synthesis.  Alberts et al. 
(1994) provided the best definition of a promoter: “the specific DNA sequence that 
directs RNA polymerase to bind to DNA, to open the DNA double helix, and to begin 
synthesizing an RNA molecule.”  Within the promoter lies a short region of regulatory 
DNA called an operator that, when occupied by a repressor protein, blocks RNA 
polymerase access to the promoter, thus preventing expression of the downstream gene 
(Alberts et al., 1994).  The presence of an inducing ligand either prevents occupancy of 
the operator or binds directly to the repressor protein, enabling RNA polymerase to bind 
to the promoter.  These inducing ligands are often referred to as inducers. 
 
Figure : Plasmid Map 
 
Constructing the recombinant DNA molecule requires a plasmid vector and 
foreign DNA, such as TEV protease or BFPTEVeGFP protein DNA.  The specific plasmid 
vector is chosen based on experimental design factors and the host cell line to ensure 
protein synthesis is optimized.  Factors to consider when selecting a plasmid include 
Origin of 
Replication 
Antibiotic resistance gene 
Promoter 
Gene  
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insert size, incompatibility with host cell machinery, selectable gene markers, cloning 
sites, promoter sites, and specialized vector functions.  Most plasmids contain a gene for 
antibiotic resistance that is used as a selection tool later in the cloning process (Stryer et 
al., 1988).  The foreign gene can be a PCR product or cut from whole DNA using 
restriction enzymes, which cleave DNA at specific amino acid sequences.  The same 
restriction enzymes are used to cut both the foreign DNA and plasmid, resulting in an 
open plasmid vector and foreign DNA molecule with overhanging complementary ends, 
called “sticky ends”.  If a PCR product is used, the primers must be designed to ensure 
the foreign DNA insert contains the appropriate complementary sticky ends.  The sticky 
ends of both the foreign DNA fragment and plasmid are connected through use of DNA 
ligase.  The result is a loop of DNA containing the foreign gene of interest.  At this point, 
the plasmid can be coupled with an in vitro transcription/translation (IVTT) system to 
express the gene product, or further processed for in vivo analysis.  Figure 10 illustrates 
the techniques used for plasmid construction and additional manipulations for IVTT and 
in vitro analysis.   
     In Vitro Transcription/Translation Systems 
 The in vitro transcription/translation (IVTT) system, also referred to as a 
cell-free protein biosynthesis system, generates proteins by using the transcription and 
translation components of cell-free extracts of prokaryotic or eukaryotic cells.  The IVTT 
system provides an alternative to in vivo protein synthesis which requires additional steps 
to transform a plasmid into the living cells and grow and culture the transformed cells.   
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Figure : Plasmid cloning techniques for IVTT and in vivo systems 
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In addition, in vivo studies require steps to break the cells and purify the proteins from the 
whole-cell lysates, which can introduce analysis challenges due to the aggregation or 
degradation of proteins within the cell.  The IVTT system provides time savings, 
flexibility to adapt the reaction conditions to the synthesized protein requirements, and 
high protein yield per unit volume (QIAGEN (1), 2005).   
 In general, the IVTT system is comprised of purified enzymes from a cell’s 
transcription and translation system.  These enzymes may be extracted and purified in 
house or purchased commercially.  Each manufacturer producing an IVTT system 
maintains proprietary rights on the ingredients (including proprietary concentrations and 
purities) in its cell-free extract products.  For example, QIAGEN uses highly productive 
E. coli cell lysates, which contain all translational machinery components such as 
ribosomes, ribosomal factors, transfer-ribonucleic acid (tRNA), aminoacyl-tRNA, T7 
RNA polymerase, and more (QIAGEN (1), 2005).  Invitrogen manufactures an IVTT 
product that that uses optimized E. coli extract containing an ATP-regenerating system, 
amino acids, and T7 RNA polymerase as well as a supplemental Feed Buffer containing a 
mixture of salts, amino acids, and other substrates that are depleted or degraded during 
protein synthesis (Invitrogen, 2006).  Shimizu et al. (2001) describe a protein synthesis 
using recombinant elements (PURE) system that contains all the necessary translation 
factors, purified with high specific activity that allows efficient protein production.  The 
choice of IVTT system should be considered during the experimental design, for each 
manufacturer recommends a specific plasmid series that will be optimized in its IVTT 
system.   
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     In Vivo Systems using Bacterial Cells 
 There are three main steps to cloning foreign DNA into a plasmid for in vivo 
analysis: constructing the recombinant DNA molecule (plasmid), introducing the 
molecule into the host cell (called transformation), and selecting cells that contain the 
recombinant DNA molecule (Stryer, 1988).   
 Transformation of the plasmid into the host cell is the process of inserting the 
plasmid DNA molecule into the host cell.  The two components are combined in a 
reaction tube and heat shocked.  As the pores of the host cell expand, the circular plasmid 
enters into the cell.  After the short heat shock treatment, a nutrient-rich medium is added 
the cooled reaction tube.  The bacteria are incubated until cell replication is sufficient for 
evaluation of the transformation process. 
 In order to select the cells that contain the plasmid, the cells are evenly spread 
onto an agar plate containing nutrients and an antibiotic which matches the antibiotic 
resistant gene on the plasmid.  The agar plate is incubated overnight to ensure sufficient 
cell growth.  Excess plasmid from the reaction mixture will not replicate on the agar, and 
cells that do not contain the plasmid will not grow in the presence of the antibiotic.  The 
resulting cell growth will be colonies from a single transformed bacterial cell containing 
the inserted plasmid.  Verification of the transformation should be performed using PCR 
with the primers for the foreign gene.  The transformed cells can be cultured for in vivo 
experiments or frozen on a bead media for future in vivo experimental use. 
In this experimental design, the TEV protease was cloned into the pET28a 
plasmid and the FRET protein was cloned into the pHWG640 plasmid.  Both plasmids 
contain promoters which utilize the T7 RNA polymerase for increased protein 
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expression.  The promoters for each plasmid house different operators and require 
separate inducing agents, which enables control of specific protein expression when both 
plasmids have been transformed into the same cell.   
All plasmids were transformed into E. coli host cells, strain BL21 (DE3).  E. coli 
host cells were chosen because they grow quickly, transform efficiently, and is a useful 
host for the biocatalytic production of small molecules.  The BL21 (DE3) strain was 
chosen for its ease of transformation with plasmid DNA and its high efficiency to express 
proteins from T7-based plasmids, such as the pET vector series.  BL21 (DE3) has been 
engineered to express T7 RNA polymerase which synthesizes mRNA more rapidly than 
E. coli RNA polymerases (Invitrogen, 2002).   
Chapter Summary 
This chapter discussed the primary components of the research designs’ sensing 
and reporter system.  The experimental design included a riboswitch to initiate translation 
of TEV protease which catalyzes proteolytic cleavage of a fluorescent fusion protein 
engineered with the TEV protease cleavage site.  The use of fluorophores for the fusion 
protein confers a FRET signal which can be measured, thereby quantifying TEV protease 
activity.  The optical output is used to demonstrate the presence of the analyte of interest.  
Techniques, such as electrophoresis, PCR, plasmid construction, IVTT, and in vitro 
systems were discussed to enhance the reader’s understanding of the experimental design. 
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III. Materials and Methods 
 
 
 Materials and methods cover performed procedures and protocols to support the 
research investigative questions.  This chapter addresses general considerations, in vitro, 
and in vivo analyses of tobacco etch virus (TEV) protease.  Throughout this chapter, the 
BFPTEVeGFP-His protein will be referred as the fluorescent resonance energy transfer 
(FRET) protein.   
General Considerations 
     Plasmid Construction 
          Materials 
The pET28a plasmid was procured from Novagen.  The TEV protease gene 
construct was generously donated by Dr. Helena Berglund, from the Department of 
Medical Biochemistry and Biophysics at the Karolinska Institute in Sweden (van den 
Berg et al., 2006).  Dr. Josef Altenbuchner, from the Institute of Industrial Genetics at the 
University of Stuttgart, contributed the pHWG640 plasmid (Gröger et al., 2005).  The 
FRET gene was engineered in the laboratory by Dr. Svetlana Harbaugh through standard 
molecular cloning techniques. 
          Methods 
All plasmid manipulations were performed according to standard cloning 
techniques.  Two different plasmid constructs containing the TEV protease gene were 
generated by cloning into the pET28a plasmid vector.  One plasmid construct harbored 
the TEV protease gene, denoted as TEV plasmid.  The other construct contained a 
riboswitch upstream of the TEV protease coding sequence, denoted as RS-TEV plasmid.  
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The plasmid vector pET28a contained a selection marker for kanamycin antibiotic 
resistance and a T7 promoter requiring isopropyl-beta-D-thiogalactopyranoside (IPTG) 
for induction of transcription and translation (Novagen, 2006).  A third plasmid construct 
containing the FRET protein gene was generated by cloning into plasmid vector 
pHWG640, which contained a selection marker for chloroamphenicol resistance and a 
rhamnose promoter.  Separate plasmids were chosen for the TEV protease and FRET 
protein to tailor co-expression during in vivo studies.  Table 1 provides a summary of all 
molecular clones used in the experiments.  
 
Table : Summary of Molecular Clones 
Plasmid Genetic Element
Activating 
Agent
Inducing 
Agent Product
pET28a TEV protease DNA IPTG TEV protease
pET28a Riboswitch mRNA Theophylline
TEV protease DNA IPTG
pHWG640 BFPTEVeGFP DNA
Rhamnose BFPTEVeGFP-His*
(FRET protein)
TEV protease
 
* The His-tag is used for purification 
 
All plasmids were transformed into the BL21 (DE3) strain of Escherichia coli (E. 
coli).  Sequences of all constructs were verified by DNA sequencing at the Plant Microbe 
Genomics Facility, Ohio State University, Columbus OH. 
     Transformation 
          Materials 
Invitrogen supplied BL21 (DE3) E. coli cells and Super Optimal Catabolite 
(SOC) medium.  Kanamycin and chloroamphenicol were purchased from Sigma.  Luria-
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Bertani (LB) agar media was purchased from Difco.  ProLabs Diagnostics supplied 
Microrank® beads. 
          Methods 
Transformation procedures followed Invitrogen One Shot® BL21 (DE3) 
protocols.  One vial of One Shot® was used per transformation.  Each vial was thawed on 
ice before addition of 10 nanograms of plasmid, in a volume of 1 to 5 microliters (μl).  
Vial(s) were incubated on ice for 30 minutes, transferred to a water bath (42oC) for 30 
seconds, and then placed on ice.  Pre-warmed SOC medium (250 μl) was added to each 
vial.  SOC medium consisted of 0.5% yeast extract, 2.0% tryptone, 10 millimolar (mM) 
sodium chloride (NaCl), 2.5 mM potassium chloride (KCl), 10 mM magnesium chloride 
(MgCl2), 20 mM magnesium sulfate (MgSO4), and 20 mM glucose.  SOC medium was 
used as a cell growth medium used to ensure maximum transformation efficiency.  Vials 
were placed on their side in an incubator and shaken at 37oC for one hour at 225 
revolutions per minute (rpm).  A volume of 20 to 100 μl of the transformation reaction 
was distributed on LB agar plates containing 25 μg/ml of the appropriate antibiotic(s) to 
inhibit growth of non-transformed bacteria.  For transformations with TEV protease and 
FRET plasmids, 25 μg/ml of both kanamycin and chloroamphenicol were added to the 
media.  For transformants with the TEV protease plasmid, 25 μg/ml of kanamycin was 
added.  For each transformation, two plates were prepared to ensure appropriate growth 
and viability. 
To maintain colony integrity for future experiments, 0.8 ml of inoculate was 
aliquoted into a Microrank® Bead vial, and then removed with a sterile pipette tip.  The 
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vial of Microrank® Beads was placed on dry ice, and then stored at -80oC until future 
use. 
Plates were inverted and incubated overnight at 37oC.  The number of colonies 
per plate was counted and the transformation efficiency calculated using the following 
formula:  
⎟⎟⎠
⎞
⎜⎜⎝
⎛=⎟⎟⎠
⎞
⎜⎜⎝
⎛×⎟⎟⎠
⎞
⎜⎜⎝
⎛×⎟⎟⎠
⎞
⎜⎜⎝
⎛
DNA plasmid μg
ants transform#
cells plated μl X
cells ed transformμl 300
μg
pg 10
DNA ed transformpg 10
colonies# 6  
 
Plates with a transformation efficiency of 1 x 108 tranformants per μg plasmid DNA or 
greater were used.  This number indicated the level of viable cells necessary for 
successful growth in cell culture experiments.   
     Protein Analysis by Polyacrylamide Gel Electrophoresis 
          Materials 
 The following materials were procured from Bio-Rad: 
trishydroxymethylaminomethane-hydrochloric acid (Tris-HCl) resolving gels (10% and 
12%), Tris/Glycine solution (10X), Tris/Glycine sodium dodecyl sulfate (SDS) solution 
(10X), Native sample buffer, Laemmli SDS reducing buffer, 2-mercaptoethanol (β-ME), 
Coomassie Blue Stain and Destain solutions, pre-stained molecular weight marker, and 
pre-stained SDS-polyacrylamide gel electrophoresis (PAGE) standard.  Bio Labs 
supplied a broad range protein marker and 2-log DNA Ladder.  Tris-Borate-Ethylene 
diamine tetraacetic acid (EDTA) (TBE) buffer solution (10X), and Tris-Acetate-EDTA 
(TAE) solution (50X) were obtained from Fisher Scientific.   
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          Non-denaturing Conditions 
 Protocols and reagent preparation for electrophoresis were adapted from Mini-
PROTEAN® 3 Cell Instruction Manual (Bio-Rad Laboratories, 2001).  The Tris-HCl 
Resolving Gel (10% or 12%) was placed in a 1X Tris/Glycine native running buffer.  
Samples to be analyzed were mixed with Native sample buffer at a 1:1 ratio prior to 
placement in wells.  Electrophoresis run time was 150 volts for 60 minutes using a Fisher 
Scientific FB300 electrophoresis power supply.  The fluorescent proteins were visualized 
using a Spectraline TP-2100E UV transilluminator using excitation wavelength of 365 
nanometers (nm), or the Clare Chemicals Research DR-88M Dark ReaderTM , emission 
range from 400 to 500 nm.  Fuji FinePix S20 pro digital camera was used to photograph 
the gels. 
          Denaturing Conditions 
 Protocols and reagent preparation for electrophoresis were adapted from Mini-
PROTEAN® 3 Cell Instruction Manual (Bio-Rad Laboratories, 2001).  The Tris-HCl 
resolving gel (12%) was placed in electrode running buffer, (1X, pH 8.3).  Samples (10 
μl) were mixed with Laemmli SDS reducing buffer (5% β−ME) at a 1:1 ratio and heated 
at 95oC on an Eppendorf Thermomixer or Fisher Scientific Isotemp 125D thermo block 
for ten minutes in order to denature the proteins.  Samples were centrifuged for one 
minute at 13000 rpm in the Eppendorf 5417R Micro-centrifuge.  The samples were 
loaded into the wells along with a broad range protein reference marker with established 
molecular weights to verify size.  Samples were electrophoresed for 60 minutes at 150 
volts using a Fisher Scientific FB300 electrophoresis power supply.  Gels were stained 
with Coomassie Blue Stain for 10 minutes, rinsed with Coomassie Destain solution for 10 
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minutes, and placed in water/destain solution over night.  Coomassie-stained SDS gels 
were visualized on a UVP TW-26 white light transilluminator and photographed. 
In Vitro Analyses of TEV Protease 
     Materials 
UltraPureTM DNase/RNAse-free distilled water and TEV buffer (20X) were 
purchased from Invitrogen.  Dithiothreitol (DTT) was obtained from Fluka.  EDTA and 
Tris base were supplied by Promega.  HCl (36%) was obtained from Sigma.  Tris-HCl 
solution, 1.5 M, pH 8.8, was obtained from Bio-Rad Laboratories.  QIAGEN supplied the 
QIAGEN EasyXpress® Kit for the in vitro transcription/translation (IVTT) system 
experiments.  Costar furnished Corning 384-well black plates with clear bottoms. 
     TEV Protease Activity Using TEV Buffer 
          Methods 
Each reaction consisted of 19.5 μl of Distilled water, DNAse and RNAse-free, 
1.25 μl of 20X TEV buffer (1 M Tris-HCl at pH 8.0; 10 mM EDTA), 2.0 μl of FRET 
protein (in TEV storage buffer, concentration of 1 μg/μl, final concentration of 0.8 
μg/μl), 0.25 μl of 0.1 M DTT, and 2 μl of TEV protease (in TEV storage buffer, varied 
concentrations), for a final volume of 25 μl per reaction.  TEV storage buffer consisted of 
50 mM Tris-HCl, pH 7.5, 1 mM EDTA, 5 mM DTT, and 10% (v/v) glycerol.  TEV 
protease was added to the reaction mixture in the following concentrations: 0, 0.074, 
0.148, 0.269, 0.741 and 1.481 μM.  The reaction with 0 μM TEV protease was evaluated 
as the negative control.  
All stock solutions were stored on ice prior to mixing.  Since the enzymatic 
reaction starts immediately upon addition of TEV protease, all reaction components were 
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mixed preceding addition of TEV protease.  Each reaction mixture (25 μl final volume) 
was transfered into Corning 384-well black plates with clear bottoms and placed in the 
SpecraMax5 fluorescent spectrophotometer (Molecular Devices) with excitation at 365 
nanometers (nm) and emission at 445 nm (corresponding to peak for BFP protein) and 
510 nm (corresponding to peak for FRET protein).  Measurement readings were taken at 
time points 0, 6, 21, 52, 113, 180 and 360 minutes.  The instrument sensitivity, defined as 
the number of readings taken per well, was set for 19 repeated measures that resulted in a 
single emission measurement for each time point.  It should be noted that time point 0 
represents the initial reading on the spectrophotometer, not the addition of TEV protease.  
Approximately five minutes elapsed between addition of TEV protease and initial 
emission reading. 
     TEV Protease Activity Using IVTT System 
 The protocols for using the IVTT system were the same as above except the 
reaction mixture consisted of 10 μl QIAGEN Reaction Buffer, 8.75 μl E. coli extract, 2.0 
μl of FRET protein, 2 μl of TEV protease (in TEV storage buffer, varied concentrations), 
and an adjusted volume of distilled water (DNAse and RNAse-free) to make a final 
volume of 25 μl per reaction. TEV protease was added to the reaction mixture in the 
following concentrations: 0, 0.269, 0.741, 1.481, and 2.962 μM.  The reaction with 0 μM 
TEV protease was evaluated as the negative control.  Measurement readings were taken 
at time points 0, 60, 120, 180, and 360 minutes.  Approximately five minutes elapsed 
between addition of TEV protease and initial emission reading. 
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In Vivo Analyses of TEV Protease 
Two main types of cell cultures were evaluated: cultures that contained both TEV 
protease and FRET plasmids, denoted as Two Plasmid Assay; and cultures that contained 
only the TEV protease plasmid, denoted as TEV Plasmid Assay.  Experiments using the 
riboswitch design with specificity to theophylline were based on research performed by 
Lynch et al. (2007) 
     Cell Culture Growth 
          Materials 
 LB-broth media was purchased from Difco.  Kanamycin, chloroamphenicol, 
theophylline, and caffeine were procured from Sigma.  Promega supplied IPTG.  L-(+)-
Rhamnose monohydrate and dimethyl sulfoxide were obtained from Fluka.  Aldrich 
supplied 2, 4-Dinitrotoluene (DNT).  RNA Protect was supplied by QIAGEN. 
     Two Plasmid Assay 
          Methods 
One flask of bacterial cells were cultured overnight from single colonies (fresh 
transformation or one Mircobank® Bead) of E. coli BL21(DE3) containing FRET protein 
gene on pHWG640 plasmid and TEV protease gene on pET28a plasmid vector in 50 ml 
LB media supplemented with the appropriate antibiotic (25 μg/ml of kanamycin and 25 
μg/ml cloroamphenicol) at 37°C and shaken at 225 rpm.  A second flask of E. coli 
BL21(DE3) cells containing the FRET protein gene on pHWG640 plasmid and upstream 
riboswitch/TEV protease gene (denoted RS-TEV) on pET28a plasmid were cultured 
under the same conditions.  Cultures were performed in triplicate.   
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Overnight cultures were separated into separate treatment culture flasks, diluted to 
1:100 in 500 ml LB media (25 μg/ml kanamycin and 25 ug/ml chloroamphenicol), and 
grown at 37°C with shaking (225 rpm) for three to four hours until reaching the mid-log 
phase.  The mid-log phase of growth was verified when cultures reached an optical 
density at 600 nm (OD600) of 0.8, as determined by Cary 300 Bio UV-Visible 
Spectrophotometer using a 1 cm path length cuvette.  Treatment cultures were performed 
in triplicate. 
When OD600  ≈ 0.8, all cultures were inoculated with rhamnose (0.4%) to initiate 
production of FRET protein.  After thirty minutes, appropriate cultures were inoculated 
with IPTG (0.5 mM) to initiate production of TEV protease and RS-TEV protease.  
Thirty minutes after IPTG addition, appropriate cultures were treated with theophylline or 
caffeine (2.5 mM).  Since theophylline is not soluble at room temperature, a 100 mM 
stock solution was prepared in DMSO (20 mg/ml) and heated in 37oC for 30 minutes.  
Table 2 represents the treatment design.  The positive control (TEV protease) represents 
cells with TEV protease plasmid and FRET protein plasmid.   
 
Table : Two Plasmid Treatment Design  
Treatment Culture Rhamnose IPTG Theophylline Caffeine
Positive Control (TEV + FRET) X X
RS-Neagtive Control (FRET) X
Riboswitch (RS) - Off X X
Riboswitch (RS) - On (Theophylline) X X X
Riboswitch (RS) - On (Caffeine) X X X  
 
Samples were collected for protein analysis (10 ml), RNA analysis (0.5 ml), and 
cell density (1 ml) over the time course illustrated in Figure 11.  Aliquots for protein 
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analysis were taken after addition of theophylline of caffeine (time point 0), and every 60 
minutes until 360 minutes.  Samples for RNA purification were aliquoted into 1.5 ml 
microcentrifuge tubes containing 1 ml RNA Protect Bacteria Reagent and collected at 
time points 0, and every 15 minutes until 120 minutes.  Aliquots for cell density were 
collected at each protein and RNA collection time point and measured at OD600.   
 
Add Rhamnose (0 hr); O.D.= 0.8 
0   30  60  90 105 120 135 150  165 180  210   240     270    330       390       450                             1320
Add IPTG
Add Theophylline
1 HR 
Post-Theo 2 HR 3 HR 4 HR 5 HR 21 HR
 
Figure : Time Course Overview for Two Plasmid Assay 
 
Extracted aliquots for protein analysis were harvested in 15 ml conical tubes by 
centrifugation in a Centra CL3-R (Thermo Electron Corporation) at 4oC for 10 minutes at 
3,200 rpm.  The supernatant (LB media) was discarded and pellets were placed on dry ice 
for an immediate quick freeze prior to storage at -80ºC for later processing.  Extracted 
aliquots for RNA analysis were vortexed and allowed to incubate at room temperature for 
5 minutes.  Samples were centrifuged at 5000 x g for 10 minutes.  The supernatant was 
discarded; pellets were placed on dry ice and subsequently stored at -80ºC until 
processing for protein extraction. 
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     Protein Extraction by Cell Lysis 
          Materials 
 UltraPureTM DNase/RNase-free distilled water was purchased from Invitrogen.  
MgCl2 was obtained from Fluka.  EDTA and Tris Base were procured from Promega.  
Sigma supplied HCL (36%), Benzonase® nuclease, lysozyme lyophilized powder (protein 
~95%), and iodoacetamide.  NaCl (5M) was obtained from Ambion.  Tris-HCl solution, 
1.5 M at pH 8.8, was obtained from Bio-Rad.   
          Methods 
The lysis protocol was adapted from QIAGEN Ni-Fast Purification of 6x His-
tagged protein under native conditions (Kohl et al., 2002).  Lysis buffer was prepared 
from 100 mM Tris-HCl, pH 8.0, 150 mM NaCl, and 1 mM MgCl2 prior to use.  For the 
Two Plasmid Assay, 8 mM iodoacetimide was added to inhibit protease activity.  The 
lysis buffer was then supplemented with 0.01% Benzonase® nuclease solution and 1% 
lysozyme solution.  The lysozyme solution was prepared by dissolving the contents of a 
lysozyme powder vial in 600 μl of native lysis buffer.   
Cell pellets were thawed for 15 min on ice and resuspended by vortexing in lysis 
buffer.  The volume of lysis buffer added to each pellet was four percent of the original 
aliquot volume.  For the Two Plasmid Assay, 200 μl of lysis buffer was added based on a 
pellet resulting from 5 ml of culture.  The resuspended cells were incubated on ice for 30 
minutes, and gently mixed two to three times by gently swirling the cell suspension.   
The Two Plasmid Assay cell lysates were centrifuged at 13,200 rpm in the 
Eppendorf 5417R Micro-centrifuge for 30 minutes at 4°C to pellet the cellular debris. 
The cell lysate supernatant, containing soluble fraction of recombinant proteins, was 
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transferred into a new 1.5 ml microcentrifuge tube and stored at -80oC.  The pellet was 
stored at -80oC in case of incomplete lysis.  
     TEV Plasmid Assay 
Cell growth and protein extraction for the TEV plasmid assay followed the same 
protocols as the two plasmid assay with the following changes: cell cultures contained 
either TEV protease or RS-TEV protease vector and were grown in 50 ml LB media 
supplemented with antibiotic (25 μg/ml of kanamycin).  Overnight cultures were diluted 
1:100 in 100 ml LB media (25 μg/ml kanamycin).  Cultures were inoculated with IPTG 
(0.5 mM) only.  Theophylline was added after 30 minutes.  Aliquots of 48 ml culture 
were collected in 50 ml conical tubes after 360 minutes and centrifuged in the Centra 
CL3-R (Thermo Electron Corporation) at 4oC for 10 minutes at 3,200 rpm.  The 
supernatant was discarded; pellets were placed on dry ice and subsequently stored at        
-80ºC until processing for protein extraction. 
Cell lysis buffer was prepared without iodoacetimide to enable TEV protease 
activity for kinetic evaluation.  Lysis was performed using 1.9 ml lysis buffer based on a 
pellet resulting from 5 ml of culture.  The cell lysates were centrifuged at 14000 x g in 
the Centra CL3-R (Thermo Electron Corporation) for 60 minutes at 4 °C.  Two aliquots 
of 190 μl were transferred into 0.5 ml tubes for purification, bicinchoninic acid (BCA®) 
protein assay, and polyacrylamide gel electrophoresis.  Two aliquots of 750 μl were 
transferred into 1.5 ml tubes for kinetic analysis.   
          Kinetic Analysis 
UltraPureTM DNase/RNAse-free distilled water and TEV reaction buffer (10X) 
were purchased from Invitrogen.  Dithiothreitol (DTT) was obtained from Fluka.  Each 
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reaction consisted of 50 μl cell lysate supernatant, 15 μl 10X TEV reaction buffer (1 M 
Tris-HCl at pH 8.0; 10 mM EDTA), 1.5 μl of 0.1 M DTT, 75 μl of 0.5 uM FRET protein 
(0.25 uM final concentration), and 8.5 μl distilled water.   
All stock solutions were stored on ice prior to mixing.  Since the enzymatic 
reaction starts immediately upon addition of TEV protease, all reaction components were 
mixed preceding addition of cell lysate supernatant.  Each reaction mixture (150 μl final 
volume) was transferred into Corning 96-well black plates and placed in the SpecraMax5 
fluorescent spectrophotometer (Molecular Devices) with excitation at 365 nm and 
emission at 445 nm (corresponding to peak for BFP protein) and 510 nm (corresponding 
to peak for FRET protein).  Measurement readings were taken every minute for 60 
minutes.  The instrument sensitivity was set for 19.  Each reaction was performed in 
duplicate. 
     RNA Purification 
          Materials 
 Bio-Rad supplied β-ME.  Ethanol (EtOH), 200 proof, was purchased from 
AAPER.  Tris-EDTA (TE) Buffer was purchased from Ambion.  QIAGEN supplied 
proteinase K, RNA Protect, RNeasy Bacteria Protect Mini kit, and EZ1 RNA Tissue Mini 
Kit.  The RNease Bacteria Protect kit contained RLT buffer, RW1 buffer, RPE buffer, 
RNAse-free water, and RNeasy spin columns.  Lysozyme and ethidium bromide (EtBr) 
was otained from Sigma.  UltraPureTM DNA-grade agarose, 10X BlueJuiceTM gel loading 
buffer, and high DNA Mass ladder were procured from Invitrogen.   
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          Methods 
 Protocols were adapted from QIAGEN RNAprotect Bacteria Reagent Handbook 
(QIAGEN (2), 2005).  For each bacterial sample which did not receive the RNA Bacterial 
Protect Reagent during the initial aliquot from the cell culture, two volumes of reagent 
were added to one original aliquot volume that yielded a sample pellet.  The pellet was 
resuspended by pipetting, vortexed for 5 seconds, and allowed to incubate at room 
temperature for 10 minutes.  After the RNA was centrifuged for 10 minutes at 5000 x g, 
the supernatant was decanted by inversion.   
For each RNA pellet, 300 μl TE + lysozyme (1mg/ml) and 10 μl proteinase K was 
added and mixed by vortexing for 10 seconds.  The mixture was incubated for 15 minutes 
at room temperature with vortexing every 2 minutes for 10 seconds.  Next, 150 μL RPE 
buffer was added and vortexed vigorously.  EtOH (750 μl) was then added to the 
supernatant and mixed by repeated pipetting. 
 Up to 700 μl of lysate sample was transferred into an RNeasy spin column and 
centrifuged for 15 seconds at 10,000 rpm on the IEC MicroMax microcentrifuge.  The 
flow-through was discarded and the remaining lysate was processed in the same manner.  
RW1 buffer (700 μl) was added to the spin column, incubated at room temperature for 5 
minutes and centrifuged for 15 seconds at 10,000 rpm.  The flow-through was discarded. 
DNase (80 μl) was added to the column and incubated for 15 minutes at room 
temperature.  A repeat wash using 620 μl RW1 buffer was accomplished, incubated at 
room temperature for 5 minutes and centrifuged for 15 seconds at 10,000 rpm.  The flow-
through was discarded.  Using a new collection tube, 500 μl of RLT buffer (with 1% β-
ME) was added to the spin column and centrifuged for 15 seconds at 10,000 rpm.  After 
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discarding the flow-through, this step was repeated with centrifugation for 2 minutes at 
10,000 rpm.  The spin column was placed in a new collection tube and centrifuged for 1 
minute at 10,000 rpm to ensure excess buffer was removed.  After placing the spin 
column in a clean 1.5 ml tube, RNase-free water (25 μl) was added to the column, 
incubated for 1 minute at room temperature, and centrifuged for 1 minute at 10,000 rpm.  
An additional 25 μl of RNase-free water was added to the column, incubated for 1 minute 
at room temperature, and centrifuged for 1 minute at 10,000 rpm.   
RNA samples (2 μl) were mixed with BlueJuiceTM (1X), for a total volume of 10 
μl, and loaded on a 1% DNA agarose gel made with TBE buffer (1X), using a TBE 
running buffer (1X) with EtBr (5ul/ml).  The EtBr binds to RNA and DNA, allowing the 
bands to be viewed on a fluorescent spectrophotometer.  A 2-log DNA ladder or a high 
DNA mass ladder was used as molecular weight standard.  Agarose gels were 
electrophoresed at 120 volts for 60 minutes and photographed on the Syngene Bio 
Imaging Systems G-Box using the transilluminator setting without filter. 
The purity and concentration of the RNA samples (1 μl) were evaluated using the 
Nano-Drop ND-1000 spectrophotometer. The remaining RNA samples were stored at -
20oC for later processing into complementary DNA (cDNA). 
     Complementary DNA (cDNA) 
          Materials 
 Invitrogen’s SuperScriptTM III Platinum® Two-Step qRT-PCR Kit with SYBR® 
Green was used to synthesize first strand cDNA from purified RNA.   The kit contents 
used during this procedure were diethylpyrocarbonate (DEPC)-treated water, 2X RT 
Reaction mixture, RT Enzyme mixture, and E.coli RNAse H. 
 47 
          Methods 
All materials were initially chilled on ice.  In a 0.5 ml microcentrfuge tube, the 
following components were combined: 10μl of 2x RT Reaction Mix; 2 μl of RT Enzyme 
Mix; 8 μl RNA (adjusted to a final concentration of 1 μg using DEPC-treated water).  For 
samples with less than 1 μg RNA, 8 μl RNA was used, and the final concentration in 
cDNA was calculated for later reference.  Each tube was gently mixed prior to the next 
step. 
All samples were placed in the ABI GeneAmp® PCR System 9700 Thermocycler, 
set with the following program: incubate at 25oC for 10 minutes; 42oC for 50 minutes; 
terminate the reaction at 85oC for 5 minutes, then remove from Thermocycler and chill 
on ice (4oC) while adding 1 μl (2 U) of E. coli RNAse H.  Samples were gently mixed 
then placed back in the Thermocycler to incubate at 37oC for 20 minutes.  Upon 
completion of the program, the samples were removed and stored at -20oC until used for 
qPCR or other analyses. 
Statistical Analysis 
 All statistical analysis was performed using GraphPad Prism, version 5.01 for 
Windows.  After the completion of each respective assay, the results from the 
SpectroMax 5 Fluorescent spectrophotometer exported to GraphPad Prism.  Statistical 
analysis for the in vitro assays compared each concentrations to the negative control.  
Statistical significance was determined by using the students t-test (one-tailed analysis 
using Welch’s correction by assuming unequal variances) at a 95 percent confidence 
level.  For in vivo assays, two-way Analysis of Variance (ANOVA) was used to compare 
means between several time points and treatments.  The Bonferroni post test was 
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performed to evaluate statistical significance at each experimental time point.  Evaluation 
was performed at 95 percent confidence interval. 
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IV. Results and Analysis 
 
 
Overview 
All experiments supported evaluation of the tobacco etch virus (TEV) protease 
and the BFPTEVeGFP-His protein for their effectiveness as a reporter pathway.  
Throughout this chapter, the BFPTEVeGFP-His protein will be referred to as fluorescent 
resonance energy transfer (FRET) protein.  Results are segregated into two categories, in 
vitro and in vivo analyses.   
For all experiments, TEV protease activity was evaluated by observing the FRET 
signal output from each reaction.  In the FRET protein construct (BFPTEVeGFP-His), the 
BFP donor emission peaked at 445 nm, whereas the eGFP acceptor emission peaked at 
510 nm when both were excited at 365 nm, as illustrated in Figure 12.   
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Figure : Spectra for Purified FRET Protein and Subcomponents   
Each line represented by 1.3 μM protein.  RFU = relative fluorescent units; 
Em = emission; Ex = excitation.  Graph provided by Dr. Svetlana Harbaugh 
(AFRL/RHPB)  
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It is important to note that the presence of BFP and eGFP together exhibited a lower 
FRET signal at 510 nm than the FRET protein.   
The ratio of emission of 510:445 nm (eGFP:BFP) was utilized to quantify the 
FRET protein signal and qualify its cleavage by TEV protease.  A higher emission ratio 
indicates a greater presence of the FRET protein due to the higher FRET signal 
(approximately 1.8 for the FRET protein in Figure 12).  Conversely, a lower ratio 
suggests greater enzyme activity as TEV protease cleaved the FRET protein into its BFP 
and eGFP components (approximately 0.7 for BFP +EGFP proteins in Figure 12).  
Because it eliminates the variability of the relative fluorescent unit measurements, the 
ratio enables signal comparisons between experiments.  
 All graphical data are presented using error bars showing standard error of the 
mean (s.e.m.).  Some error bars are relatively small and are not visible beyond the data 
point symbol.  S.e.m. is a measure of the precision of the data, as opposed to the measure 
of variability when using standard deviation (Motulsky & Christopoulos, 2006).  S.e.m. is 
commonly used experimental biology when comparing samples from two groups to infer 
if the two groups are different (Cumming et al., 2007).   
In Vitro Analyses of TEV Protease 
TEV protease activity was examined using varying concentrations of purified 
TEV protease to cleave 1.38 μM FRET protein in a buffer and an in vitro translation and 
transcription (IVTT) system over time.  An additional experiment using the TEV plasmid 
(circular DNA containing TEV protease gene) was evaluated in the IVTT system.  For all 
experiments, the negative control contained FRET protein (no TEV protease) to establish 
a baseline FRET signal.   
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The goals of these experiments were to determine the following: (1) if the TEV 
protease and FRET protein interaction resulted in a discernable output signal in different 
systems, and (2) the effect of the IVTT system on that output when compared to an ideal 
buffer system.  Based on the literature review, the FRET protein design was expected to 
result in a robust output signal when cleaved by TEV protease.  The buffer system 
represented ideal conditions for enzymatic reactions due to the lack of DNA and other 
cellular machinery which participates in protein synthesis in the in vivo system.  The 
IVTT system simulated in vivo conditions with minimal background protein synthesis of 
other gene products due to absence of DNA.  The FRET signal from both systems was 
expected to be similar.  The FRET signal from the TEV plasmid in the IVTT system was 
expected to be similar to the purified proteins in the IVTT system, though the signal at 
the 0 minute time point was expected to be lower since the TEV protease required 
manufacturing by the IVTT system components before cleaving FRET protein.  The 
negative control signal was expected to remain the same over the time course since no 
TEV protease was present to initiate cleavage.   
Figure 13 displays TEV protease activity on 1.38 μM FRET protein in a buffer 
system (1M Tris-HCl at pH 8.0; 10 mM EDTA).  As expected, the negative control (0 
μM TEV protease) emission ratio remained stable (mean = 4.588, s.e.m. = 0.015) and 
thus is a valid control condition.   
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Figure : TEV Protease Cleavage of 1.38 μM FRET Protein in Buffer System 
 Excitation at 365 nm.  n=2; error bars represent s.e.m.  Data was analyzed using 
column statistics of tabulated data on GraphPad Prism version 5.01 for Windows. 
 
Using the student’s one-tailed t-tests with Welch’s correction (assuming unequal 
variances), varied concentrations of TEV protease were evaluated against the negative 
control (0 μM TEV protease) to determine if the difference in enzyme activity was 
statistical significance.  Statistical significance is indicated by an asterisk (*) based on p < 
0.05 in Table 3 below.   
 
Table : Statistical Analysis for In Vitro Buffer System 
    0     6    21    52   113   180   360
0     & 0.074 0.320 0.283 0.281 0.457 0.258 0.082 0.136
0     & 0.148 0.373 0.422 0.168 0.069 0.028* 0.009* 0.006*
0     & 0.296 0.105 0.077 0.023* 0.026* 0.032* 0.030* 0.024*
0     & 0.781 0.030* 0.020* 0.010* 0.000* 0.003* 0.001* 0.001*
0     & 1.481 0.037* 0.036* 0.026* 0.030* 0.006* 0.003* 0.001*
TEV Protease Concentration 
Comparisons (uM)
Time  (minutes)
 
Probability values from student’s one-tailed t-test using Welch’s correction between negative control (0 uM 
TEV protease) and varied concentrations of TEV protease in a TEV buffer system.  Data analyzed on 
GraphPad Prism version 5.01 for Windows.  Legend: * p < 0.05.   
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No statistical difference was observed between 0 μM and 0.074 μM TEV 
protease.  Concentrations of TEV protease at 0.074 μM and 0.148 μM were not used in 
further experimentation because their activity was significantly lower than the higher 
concentrations of TEV protease.  Statistical significance was observed between 0 uM and 
both 0.781 μM and 1.148 μM TEV protease concentrations for all time points.  Emission 
measurements and statistical analysis showed that a TEV protease:FRET protein ratio of 
0.5 or higher resulted in measurable and predictable signal change.  The reporter pathway 
will produce a robust output signal when concentrations of the protease and its substrate 
are controlled.   
The factor of time was considered in order to evaluate the effectiveness of the 
reporter system.  Based on the 1.481 μM TEV Protease concentration curve, a significant 
amount of enzyme activity occurred within the first 120 minutes, followed by reduced 
activity as the FRET protein concentration declined.  After 360 minutes, the emission 
ratio dropped below one, indicating most, if not all, FRET protein had been cleaved.  
Examination of the change in emission ratio over 360 minutes illustrated that the 1.481 
μM TEV protease concentration produced a discernable signal change when compared to 
the negative control (0 μM TEV protease concentration), as presented in Figure 14.  The 
difference between the emission ratios was statistically significant at p < 0.001 using 
student’s t-test (Table 3), further validating the operational value of the reporter assay. 
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Figure : Emission Ratio Difference (t0-t360) in Activity for Buffer System  
Emission at 365 nm.  n=2; error bars represent s.e.m.  0 μM: x = 0.09; 1.48 μM: 
x =2.71. Data analyzed using column statistics of tabulated data on GraphPad 
Prism version 5.01 for Windows. 
 
The results for TEV protease activity using the IVTT system were quite different, 
as illustrated in Figure 15.  Although the negative control was expected to maintain a 
steady ratio, it decreased over the time course with a wide error (mean = 1.856, s.e.m. ± 
0.238).   
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Figure : TEV Protease Cleavage of 1.38 μM FRET Protein in IVTT System 
Excitation at 365 nm.  n=3; error bars represent s.e.m.  Data analyzed using column 
statistics of tabulated data on GraphPad Prism version 5.01 for Windows. 
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Parallel research was performed by John Lynch (AFRL/RHPB) on the 
effectiveness of the IVTT system to express TEV protease from the TEV protease gene 
cloned into the pET28a plasmid vector.  Experimental methods were the same used for 
the TEV protease in the IVTT system, with two substitutions: purified TEV protease was 
replaced by pET28a_TEV plasmid and 0.25 μl of water was replaced with the same 
volume of IPTG (10 mM) to induce transcription.  The data, illustrated in Figure 16, was 
included to compare different parameters between experimental designs.   
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Figure : TEV Plasmid Cleavage of 1.38 μM FRET Protein in IVTT system 
Excitation at 365 nm.  n=2, error bars represent s.e.m. Data analyzed using column 
statistics of tabulated data on GraphPad Prism version 5.01 for Windows. Data 
provided by Mr. John Lynch (AFRL/RHPB). 
 
Comparison of emission ratios between the negative control (0 mM TEV 
protease) and the TEV plasmid product was evaluated using the student’s one-tailed t-
tests with Welch’s correction assuming unequal variances (refer to Table 4).  Statistical 
significance, indicated by an asterisk (*) based on p < 0.05, was observed for all time 
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points except 0 minutes.  The emission ratio at 0 minutes was expected to be similar since 
the TEV protease must be expressed from the TEV plasmid using the components in the 
IVTT reaction buffer.  The statistical significance at the later time points indicated that 
TEV protease was successfully expressed within the IVTT system. 
 
Table : Statistical Analysis for TEV Plasmid in IVTT System 
0 60 180 360
0.3179 0.0148* 0.0173* 0.0117*
Time (minutes)
 
Probability values from student’s one-tailed t-test using Welch’s correction between Negative 
Control (no plasmid) and TEV plasmid in IVTT system.  Data analyzed on GraphPad Prism 
version 5.01 for Windows. Legend: * p < 0.05. 
 
 Comparison of the negative controls for all experimental designs demonstrated 
significant differences between the Buffer and IVTT systems (Figure 17).   
 
 
Figure : Comparison for Negative Controls between Different In Vitro Systems 
Excitation at 365 nm.  n=2, error bars represent s.e.m.  Data analyzed using column 
statistics of tabulated data on GraphPad Prism version 5.01 for Windows 
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Evaluation of the emission ratio difference between the negative controls of the 
Buffer system and both the IVTT system experiments verified that the FRET signal 
dropped significantly in the IVTT system (see Figure 18).   
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Figure : Emission Ratio Differences (t0-t360) for In Vitro Systems 
Excitation at 365 nm; Buffer system, x = 0.09, n=2; IVTT System, x = 
1.32, n=3; IVTT Plasmid, x = 0.67, n = 3; error bars represent s.e.m.  
Data analyzed using column statistics of tabulated data on GraphPad 
Prism version 5.01 for Windows. 
 
The emission ratio of the negative control in all experiments should have 
remained constant throughout the 360 minute time frame because no enzyme-substrate 
reaction should exist.  Using the two way ANOVA, there was statistical significance 
between the buffer system and IVTT System/IVTT Plasmid experiments (p= 0.026 and 
 58 
0.038 respectively) but no statistical significance between within the IVTT system (p = 
0.242).  Possible explanations for the large emission change include degradation of the 
FRET protein due to side reactions in the IVTT reaction mixture or accumulation of by-
products from the IVTT reaction that mask the FRET protein emission.  It is also possible 
that the complex matrices of the IVTT system induce a conformational change in the 
FRET protein and shift the fluorophores outside the Förster resonance distance of 100 Å.   
In addition to the large emission range displayed by the negative control in IVTT 
system experiments, the emission ratio of all concentrations was lower than that of the 
Buffer system by a factor of two as illustrated in Figure 19.  
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Figure : Mean Emission Ratios of 0 μM TEV Protease for In Vitro Systems 
 Buffer system, x = 4.59, n=2, IVTT System, x = 1.86, n=3, IVTT Plasmid x = 1.96, n 
= 2; error bars represent s.e.m.  Data analyzed using GraphPad Prism version 5.01 for 
Windows. 
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The mean emission ratios of both IVTT system experiments was not statistically 
significant (p = 0.3566), where as the mean between the Buffer and IVTT systems was 
statistically significant (p = 0.002).  Natural molecules often contain chromophoric 
moieties that have characteristic spectra (Boyer, 1993).  In addition, proteins absorb light 
as well as diffract light when bombarded with light.  Because the IVTT system utilized 
components from cell extracts, the background fluorescence of the IVTT reaction buffer 
components interfered with the FRET signal in a non-uniform manner over time.   
To determine if the negative control emission change in the IVTT System (using 
purified TEV protease) was due to FRET protein cleavage, degradation, or 
conformational change, non-denaturing polyacrylamide gel electrophoresis (PAGE) was 
performed (Figure 20).  Purified FRET protein (30 μg) was used as a standard and each 
well contained 20 μl reaction mixtures (16 μg FRET protein).  No significant degradation 
of the negative control occurred from zero minutes to 360 minutes since the band 
intensity remained visually constant.     
 
 
Figure : Non-denaturing PAGE of IVTT System with FRET protein 
12% Tris-HCl non-denaturing gel; Pure FRET: 30 μg FRET protein; 
Negative Control: 16 μg FRET protein.  Photo taken on Dark Reader (ex: 
400-500 nm) with Fuji Camera. 
 
 Pure     \--Negative Control (minutes)--/ 
FRET      0         60      120     180    360  
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These results reinforce the supposition that the background fluorescence of the IVTT 
components were interfering with the FRET protein emission and that the lowered 
emission ratio was not a result of FRET protein cleavage. 
The same gel was stained with Coomassie Blue staining solution (Figure 21) 
indicated numerous other proteins of different molecular weights were present in the 
negative control reaction mixture when using the IVTT system.  These other proteins 
contributed to the background fluorescence that masked the FRET protein emission when 
taken on a spectrophotometer.   
 
 
Figure : Non-denaturing PAGE of IVTT System with Coomassie Blue Stain 
12% Tris-HCl non-denaturing gel; Pure FRET: 30 μg FRET protein; Negative 
control: 16 μg FRET protein. Photo taken on Bio Imaging Systems G-Box.  
 
Though the negative control displayed anomalous behavior and emission ratio 
was lower than the buffer system due to background fluorescence, it was assumed that 
the IVTT reaction behavior would be consistent within all reactions mixtures and 
comparisons could be made between the different TEV protease concentration and the 
negative control (0 μM TEV protease).  Comparisons were made using the student’s one-
tailed t-tests with Welch’s correction (assuming unequal variances).  Statistical 
significance is indicated by an asterisk (*) based on p < 0.05 in Table 5 below.  Statistical 
 Pure     \--Negative Control (minutes)--/ 
FRET      0       60        120     180     360 
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significance was observed between 0 μM and both 1.148 μM and 2.962 μM TEV 
protease concentrations for all time points.  These results were consistent with results 
obtained when using the buffer system.   
 
Table : Statistical Analysis for IVTT System 
    0 60 120   180   360
0     & 0.296 0.318 0.072 0.017* 0.016* 0.013*
0     & 0.781 0.108 0.018* 0.005* 0.006* 0.008*
0     & 1.481 0.000* 0.010* 0.003* 0.005* 0.007*
0     & 2.962 0.000* 0.010* 0.003* 0.005* 0.008*
1.481    & 2.962 0.017* 0.015* 0.388 0.059 0.156
TEV Protease Concentration 
Comparisons (uM)
Time  (minutes)
 
Probability values from student’s one-tailed t-test using Welch’s correction between negative control (0 uM 
TEV protease) and varied concentrations of TEV protease in IVTT system.  Data analyzed on GraphPad 
Prism version 5.01 for Windows.  Legend: * p < 0.05.   
 
An additional analysis was performed between 1.148 μM and 2.962 μM TEV 
protease concentrations because of their graphical results.  Statistical significance was 
observed only at 0 and 60 minute time points, indicating the higher TEV protease 
concentration produced a more discriminating signal than the lower concentration.  
Limited inferences were made for TEV activity in the IVTT system given that the 
negative control could not be validated and inability to remove background fluorescence. 
Additional insight into TEV activity was obtained by comparing results between the 
buffer and IVTT system, and the purified TEV protease and the TEV plasmid in the 
IVTT system (Figure 22).  All experiments used the same concentration of purified FRET 
protein (1.38 μM).  To maintain consistency with comparisons, parameters were matched 
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where possible.  Results could only be inferred for the IVTT-pET28a TEV assay because 
the exact concentration of TEV protease was not determined.   
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Figure : TEV Protease Cleavage of 1.38 μM FRET Protein in Different Systems 
Excitation at 365 nm.  n=2, error bars represent s.e.m.  Data analyzed using column 
statistics of tabulated data on GraphPad Prism version 5.01 for Windows  
 
Two-way analysis of variance (ANOVA) with a Bonferroni post test was used to 
evaluate the different experiments.  Two-way ANOVA indicated statistical significance 
between all interaction (p < 0.0001) of time and experiment type.  As expected, time 
demonstrated statistical significance (p < 0.0001).  Variances between the experiments 
types resulted in p = 0.0023, indicating each experiment produced statistically different 
results; however, results of the Bonferroni post test (Table 6) indicated no statistical 
significance between experiments performed within the IVTT system.  For all experiment 
types, no statistical significance was noted after 180 minutes, indicating that the all FRET 
protein in the reaction had been cleaved.   
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Table : Statistical Analysis for All In Vitro Systems 
    0 60   180   360
1.48 uM TEV in Buffer   &   1.48 uM TEV in IVTT *** *** ns ns
1.48 uM TEV in Buffer   &    TEV Plasmid in IVTT *** * ns ns
1.48 uM TEV in IVTT    &    TEV Plasmid in IVTT ns ns ns ns
Bonferroni Comparisons
Time  (minutes)
 
Data analyzed using two-way ANOVA with Bonferroni post-test on GraphPad Prism version 5.01 for 
Windows.  Legend: ns = not significant, * p < 0.05; *** p <0.001 
 
In summary, the in vitro experiments verified that the TEV protease cleaved the 
FRET protein as designed, and the reaction output signal was strongest at a TEV 
protease: FRET protein ratio of 0.5 or higher.  Though reactions in the Buffer System 
demonstrated larger emission ratios, the both IVTT system experiments successfully 
confirmed a discernable output signal, indicating the reporter pathway might be 
successful when utilized within in vivo (cell-based) studies.  Given that the IVTT system 
displayed a non-uniform pattern of fluorescence interference as well as a lack of TEV 
protease production when placed under the control of the riboswitch (data not shown), 
determination of the interfering IVTT components was not pursued further. 
In Vivo Analyses of TEV Protease 
In vivo assays offer more flexibility for development of modular sensor-reporter 
systems because machinery of the host cell can be used to translate and transcribe the 
reporter pathway components; thereby reducing reliance upon expensive IVTT systems.  
However, cell-based assays introduce greater complexity to the analysis of enzyme 
reactions because the output signal is affected by side-reactions and background 
fluorescence of the entire system.   
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TEV protease activity was examined through the use of two different in vivo 
assays.  The TEV Plasmid Assay evaluated the kinetic activity of the enzyme whereas the 
Two Plasmid Assay evaluated the behavior of the TEV protease when co-expressed with 
the FRET protein.  Table 7 summarizes the assays and their end products.   
 
Table : Summary of In Vivo Assays 
Assay Title Plasmid End Products
Two Plasmid Assay pET28a TEV  & RS-TEV proteins
pHWG640 FRET protein
TEV Plasmid Assay pET28a TEV  & RS-TEV proteins  
 
The goals of these experiments were to evaluate TEV protease activity in an in 
vivo setting and introduce the riboswitch as a genetic regulator to determine its kinetics 
via the output of the reporter pathway.   
     Two-Plasmid Assay 
In the Two Plasmid Assay, TEV protease and FRET protein were co-expressed 
from plasmids in the same cell (Figure 23).  Protein was expressed for 30 minutes prior to 
introducing experimental treatments and analysis.  TEV protease and TEV protease 
containing the riboswitch (RS-TEV) were prepared from two separate cell cultures.  
Treatments to the RS-TEV design included riboswitch activation by theophylline and its 
caffeine relative, and no riboswitch activation.  It was expected that the RS-TEV On 
treatment with theophylline would closely match results from the TEV positive control 
(no riboswitch) because both would express the TEV protease.  The RS-TEV On 
treatments with theophylline and caffeine were expected to be different since the 
riboswitch design was based on research presented by Lynch et al. (2007) that reported 
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reactions specific to theophylline but not caffeine.  Caffeine differs from theophylline by 
a methyl group (refer to Figure 5, Chapter II) and was used to gauge riboswitch 
specificity for the ligand.  The RS-TEV treatment with caffeine was expected to overlap 
the RS-TEV Off treatment because the conformation of the riboswitch for both 
treatments should inhibit translation initiation.    
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Figure : Emission Ratio from Two Plasmid Assay  
Excitation at 365 nm.  n = 3 for RS Off, RS On (Caffeine); 
n=6 for RS On (Th) and TEV Positive Control; error bars 
represent s.e.m.  Analysis performed using Non-linear 
regression on GraphPad Prism version 5.01 for Windows. 
 
 The higher emission ratios of the RS-TEV On with theophylline treatment when 
compared to the TEV positive control indicated less FRET cleavage.  One possible 
explanation could be that insertion of the riboswitch upstream of the TEV protease gene 
hindered translation of the TEV protease, resulting in a lower protein yield.   
The RS-TEV On treatment with theophylline demonstrated higher TEV protease 
activity than that with its caffeine competitor.  Statistical analysis performed using two-
way ANOVA indicated significance between time points (p < 0.0001) and treatments (p 
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< 0.0001); however, the Bonferroni post test (Table 8) implied some treatments produced 
similar results for 180 minutes, and then became statistically different.  The inference 
from these results indicated the riboswitch does not provide absolute specificity for 
theophylline; there is a slight conformational change of the riboswitch in the presence of 
caffeine which allowed ribosome binding and translation initiation.  At least 240 minutes 
were required to discriminate between riboswitch on, off, and a non-specific ligand 
(caffeine).  In essence, this time distinguishes between a positive and false positive 
reading.  In addition, the RS-TEV On with caffeine treatment appeared to express some 
quantity of TEV protease because its emission ratio was lower than the RS-TEV Off 
treatment, though the Bonferroni post test indicated no statistical significance.   
 
Table : Statistical Analysis for In Vivo Two Plasmid Assay 
Bonferroni Comparisons 0 60 120 180 240 300 360
TEV Ctrl        &   RS-On ns *** *** *** *** *** ***
TEV Ctrl        &   RS Off ns *** *** *** *** *** ***
TEV Ctrl        &   RS-On (Caff) ns *** *** *** *** *** ***
RS On (Th)    &   RS-OFF ns ns *** *** *** *** ***
RS On (Th)    &   RS On (Caff) ns ns ns *** *** *** ***
RS On (Caff)  &   RS-OFF ns ns ns *** ns * ns
Time (minutes)
 
Data analyzed using two-way ANOVA with Bonferroni post-test on GraphPad Prism version 5.01 for 
Windows.  Legend: ns = not significant, * p < 0.05; *** p < 0.001. 
 
A difference between RE-TEV On with theophylline and RS-TEV Off treatments 
was expected after 60 minutes of protein expression, but was not statistically significant 
until 120 minutes, indicating the RS-Off treatment also expressed low levels of TEV 
protease.  This observation was supported by results reported by Lynch et al. (2007) that 
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the riboswitch did not completely repress protein translation of the TEV protease, 
resulting in background noise.   
 To validate measurements from the spectrophotometer, 20 μl aliquots RS-TEV on 
with theophylline were extracted at specified time points for non-denaturing gel 
electrophoresis (Figure 24).  The TEV assay consisted of purified FRET protein, BFP, 
and eGFP proteins.  The gel illustrates the production of FRET protein and TEV protease 
over time as well as the TEV protease activity cleaving the FRET protein into its BFP 
and eGFP constituents.  The emission signal became discernable to the naked eye after 
240 minutes, suggesting this is the minimal reaction time required to verify TEV protease 
activity in the presence of theophylline. 
 
 
Figure : Non-denaturing Gel of TEV Protease Activity with Riboswitch On 
Riboswitch On (2.5 mM theophylline).  12% Tris-HCl Native gel.  Photo taken on 
UVP TW-26 white light transilluminator (ex: 365 nm) with Fuji Camera. 
 
Analysis of purified total RNA on a 1% agarose gel indicated the presence of the 
two ribosomal subunits, 50S (top) and 30S (bottom), in E. coli cellular mRNA (Figure 
24).  Visualizing the mRNA in the Agarose gel assists in assessing presence and purity of 
the mRNA.  Bands that were not well defined or appeared to have smeared in the gel 
indicated degradation of the mRNA (Figure 25, top).  Well-defined bands indicated 
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        60      120       180      240       300       360      Assay 
FRET 
BFP 
eGFP 
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mRNA with higher level of purity (Figure 25, bottom).  The level of intensity was an 
indication of concentration.  Determination of concentration and purity were quantified 
on the NanoDrop® spectrophotometer.  
 
 
 
Figure : Purified Total RNA for RS-TEV On 
Top band of both photos represent 50S ribosomal subunit while 
lower band is 30S subunit. Top photo indicates mRNA degradation 
while lower photo indicates higher purity, but lower concentration. 
mRNA evaluated on 1% agarose gel.  Photos taken on Bio Imaging 
Systems G-Box.  
 
Purified mRNA was used to produce complementary DNA (cDNA) for analysis 
by real time polymerase chain reaction (qPCR), which evaluates lifespan of the mRNA 
through multiple polymerase cycles as well as differentiating mRNA from different 
genes.  Unfortunately, there were challenges developing a standard curve for the TEV 
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protease and FRET protein, so further evaluation was discontinued for the duration of this 
study. 
     TEV Plasmid Assays 
In the TEV Plasmid Assay, TEV protease was expressed for 360 minutes to 
maximize concentration for kinetic experiments (Figure 26).  Kinetic reactions were 
analyzed after addition of 0.25 μM FRET protein.  All data was normalized to account 
for total protein concentration (see appendix B for process).  In these experiments, the 
RS-TEV On treatment was expected to closely align with the TEV positive control (no 
riboswitch) because TEV protease should be produced in both designs.  The RS-TEV off 
treatment should produce the highest emission signal ratio because TEV protease should 
not be expressed and the FRET protein should be prevalent. 
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Figure :  Emission Ratio from TEV Plasmid Assay  
Excitation at 365 nm. n=2, error bars represent s.e.m.  Data 
analyzed using non-linear one phase exponential decay on 
GraphPad Prism version 5.01 for Windows. 
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Results from the TEV Plasmid assay and subsequent statistical analysis further 
validated the effectiveness of the riboswitch to regulate gene expression in the presence 
of theophylline.  Results also demonstrated that the presence of the riboswitch on the 
TEV plasmid reduced protein expression, resulting in a high signal ratio than the TEV 
positive control which does not harbor the riboswitch. 
Two-way ANOVA indicated significance between time points (p < 0.0001), 
treatments (p = 0.0009), and all interactions (p < 0.0001).  The Bonferroni post tests 
indicated statistical difference between the TEV positive control and both RS-TEV On 
and RS-TEV Off treatments (see Table 9).  The mixed significance levels between the 
RS-TEV On and RS-TEV Off are likely due to the small number of replicates and the 
early time points.  The results of the TEV Plasmid Assay should parallel the in vitro 
analyses; however, comparisons could not be generated due to the differing experimental 
treatments. 
Table : Statistical Analysis for In Vivo TEV Plasmid Assay 
0 15 30 45 60 75 90 105 120
Positive Control TEV    &   RS-TEV On ns *** *** *** *** *** md *** ***
Positive Control TEV    &   RS-TEV Off ns *** *** *** *** *** md *** ***
RS-TEV On    &   RS-TEV Off ns ns ** ns * *** md *** ***
Time (minutes)
Bonferroni Comparisons
 
Data analyzed  using two-way ANOVA with Bonferroni post-test  on GraphPad Prism version 5.01 for 
Windows.  Legend: ns = not significant, * p < 0.05; ** p < 0.01;*** p < 0.001, md = missing data 
 
The data indicated that the riboswitch in the RS-TEV off treatment did not 
completely repress expression of the TEV protease; otherwise there should be no change 
in emission signal over the 120 minute time course.   
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Summary 
In summary, both in vivo assays demonstrated the ability of the sensing element 
and reporter pathway to signal the presence of an analyte of interest.  At least 60 minutes 
were required to distinguish the reporter signal from a control, whereas 240 minutes were 
required to distinguish between the on, off, and non-specific analyst reporter signals.  
These studied also provided evidence that introduction of the riboswitch impacts the rate 
of TEV protease production, but no protease-substrate activity.  Background noise 
lowered the signal output but did not significantly affect interpretation of the results. 
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V. Conclusions 
 
 
Overview 
 The research outlined in this thesis supports the larger research project by 
AFRL/HE to develop a modular synthetic biology-based system that detects and reports 
the presence of a threat agent.  The focus of this thesis was to characterize the enzyme-
substrate interactions in the synthetic system to accurately report the presence of a 
molecule of interest.  Specifically, I investigated the signal output resulting from tobacco 
etch virus (TEV) protease cleavage of a fluorescence resonance energy transfer (FRET) 
protein.  The investigation included evaluation of the theophylline-dependent riboswitch 
sensing element to produce a reportable signal.  This chapter provides a summary of the 
study by revisiting the research questions initially posed in addition to a description of 
continuing studies and recommendations for future research.   
Research Questions Revisited 
1. Does the TEV protease and fluorescent fusion protein interaction result in a robust 
output signal? 
Both in vitro and in vivo analyses demonstrated detectable and differentiated 
signals when compared to a control.  For in vitro evaluation, the fluorescent signal 
strength was dependent on enzyme concentration. A minimal enzyme: substrate ratio of 
1:2 was required for a valid signal.  The in vivo reactions also emitted a differentiated 
signal but produced background noise which interfered with the signal output.   
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2. How will enzyme-substrate interaction behave in different systems?  
a. Buffer System, in vitro transcription translation system (IVTT), and in vivo 
system 
The TEV protease and FRET protein interactions effectively demonstrated a 
defined and differentiated output signal to be of value in a sensing and the reporter 
system.  In vitro assays were more effective for screening modified enzymes or substrates 
in the reaction mixture.  Should any components of the reporter pathway be changed, in 
vitro analysis using the Buffer system would validate the reaction, while the IVTT system 
would provide insight into expected signal output using in vivo techniques.  Both 
analyses can be performed in one day without the time consuming culture growth and 
protein extraction steps.  In vivo studies validated production of TEV protease and FRET 
protein using the cell’s machinery to translate and transcribe their genes.  The cellular 
environment may be more adaptable to platform design for field use or pathway 
encapsulation. 
b. What is the time factor for the earliest distinguishable output signal? 
Differentiated output signals from the reporter pathway reaction were detectable 
as early as 60 minutes using in vitro techniques.  With the introduction of a genetic 
sensing element for the in vivo studies, a detectable signal was observed after 60 minutes 
when compared to a negative control, but 240 minutes was required to distinguish 
activity between the target analyte and a competitor.  
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3. Will introduction of a sensing element (riboswitch) negatively affect the downstream 
reporter system and output signal?  
Riboswitch insertion only applied to the in vivo assessment.  The sensing element 
was able to regulate transcription activity in a ligand-dependent fashion, but required a 
minimum reaction time of 240 minutes reaction to ensure the signal could be 
distinguished from a false positive result.  The presence of the riboswitch reduced TEV 
protease expression and impacted signal output as compared to the TEV protease gene 
without the upstream riboswitch.  
The TEV Protease Assay demonstrated the impact of signal interference from 
background fluorescence.  It reinforced results for the Two Plasmid Assay by 
demonstrating the riboswitch gene regulation in the presence or absence of theophylline.  
Because the replications for this experiment were low (n=2), the experiment should be 
repeated to gain more insight into the kinetic behavior of the TEV protease generated 
from different plasmid designs. 
The background fluorescence from cellular molecules found in the IVTT and in 
vivo experiments was a major factor that interfered with the reporter system design.  
Continuing and Future Research 
Experimentation performed for this thesis supported a larger research design 
evaluated by the Air Force Research Laboratory (AFRL).  Progress on the sensing and 
reporter system proof-of-concept was reported to the Air Force Office of Scientific 
Research (AFOSR) in January 2008.  AFOSR authorized additional studies on 
encapsulation systems and riboswitch design modifications to recognize different ligands.  
AFRL/RH is evaluating an alternate FRET protein construct, based on research 
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performed by Ganesan et al. (2006), which squelches output signal in its fusion protein 
form but emits a signal after catalytic cleavage.   
This research validated genetic control by riboswitch insertion upstream of an 
enzyme gene.  One recommendation for future research is to evaluation of alternative 
reporter designs, such as substituting the enzyme-substrate pathway with a direct 
riboswitch control of the fluorescent protein gene.  Yen et al. (2004) reported insertion of 
a self-cleaving ribozyme upstream of the reporter gene.  In the absence of a regulator 
(“off” mode), the reporter protein was not expressed because the mRNA coded for self-
cleavage and destruction.  In the presence of a regulator, the self-cleaving RNA motif 
was inactivated and protein translation proceeded.  Simplifying the sensing and reporter 
system potentially reduces interference from other biological activities and may increase 
modularity.  Such evaluations would need to be considered when investigating 
encapsulation systems.   
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Appendix A: Acronyms and Abbreviations 
 
 
 
Acronym Definition 
AFOSR Air Force Office of Scientific Research 
AFRL Air Force Research Laboratory 
DNA deoxyribonucleic acid 
 cDNA complementary DNA 
DTRA Defense Threat Reduction Agency 
E. coli Escherichia coli 
FRET fluorescence resonance energy transfer 
GFP mutants green fluorescent protein 
 BFP blue fluorescent protein 
 CFP cyan fluorescent protein 
 eGFP enhanced green fluorescent protein 
 YFP yellow fluorescent protein 
IED improvised explosive device 
IVTT in vitro transcription/translation 
N  nitrogen 
NIa Nuclear Inclusion a 
p probability 
PAGE  polyacrylamide gel electrophoresis 
PCR polymerase chain reaction 
 qPCR real-time polymerase chain reaction 
 RT-PCR real time polymerase chain reaction 
PURE Protein synthesis Using Recombinant Elements 
QDR Quadrennial Defense Review 
RBS ribosome binding site 
RH Human Effectiveness Directorate 
RNA ribonucleic acid 
 mRNA messenger RNA 
rpm revolutions per minute 
RS-TEV riboswitch-tobacco etch virus 
s.e.m. standard error of the mean 
SPAWAR Space and Naval Warfare Center 
TEV tobacco etch virus 
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Appendix A: Acronyms and Abbreviations (continued) 
 
 
 Acronym Definition 
Amino 
Acids: 
 Asn (N) asparagine 
 Asp (D) aspartic acid 
 Gln (Q) glutamine 
 Glu (E) glutamic acid 
 Gly (G) glycine 
 His (H) histidine 
 Ile (I) isoleucine 
 Leu (L) leucine 
 Phe (F) phenylalanine 
 Pro (P) proline 
 Ser (S) serine 
 Thr (T) threonine 
 Tyr (Y) tyrosine 
Chemicals: 
 BCA bicinchoninic acid  
 β-ME 2-mercaptoethanol  
 DEPC diethylpyrocarbonate  
 DMSO dimethyl sulfoxide 
 DTT dithiothreitol  
 EDTA  ethylene diaminete traacetic acid  
 EtBr ethidium bromide  
 EtOH ethanol  
 HCl hydrogen chloride 
 IPTG isopropyl-beta-D-thiogalactopyranoside  
 KCl potassium chloride 
 LB media/agar Luria-Bertani media/agar 
 MgCl2 magnesium chloride hexahydride  
 MgSO4 magnesium sulfate 
 NaCl sodium cloride 
 Ni2+ Nickel (elemental) 
 SDS sodium dodecyl sulfate 
 SOC Super Optimal Catabolite  
 TAE Tris-Acetate-EDTA  
 TBE Tris-Borate-EDTA  
 TE  Tris-EDTA  
 Tris trishydroxymethylaminomethane 
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Appendix A: Acronyms and Abbreviations (continued) 
 
 
 Acronym Definition 
measurements 
 Å angstrom 
 oC degrees Celsius 
 kb kilo base 
 kDa kilo Dalton (measure of atomic mass) 
 OD600 optical density at 600 nm 
 pH measure of acidity or alkalinity 
 mg/mg milligram/milliliter (10-3) 
 μg/μg microgram/microliter (10-6) 
 ng/nm nanogram/nanometer (10-9) 
 μM/mM micromolar/millimolar  
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Appendix B: Normalizing Kinetic Data  
 
Materials: Bicinchoninic acid (BCA®) Protein Assay was purchased from Pierce. 
 
Step 1: Measure absorbance readings of standard protein concentration over a range of 
concentrations.  
 
Results: 
Standard concentration 
(ug/ml) Abs Abs Avg Abs 
0 0.0860 0.0854 0.0857
25 0.1118 0.1105 0.1112
125 0.2833 0.2799 0.2816
250 0.4682 0.4710 0.4696
500 0.8246 0.8142 0.8194
750 1.0889 1.0812 1.0851
1000 1.4888 1.4963 1.4926
1500 1.8201 2.0673 1.9437  
 
 
 
Step 2: Develop standard curve by plotting average absorbance by standard 
concentration. Plot a trend line and define formula  
 
Standard Curve y = 0.0013x + 0.1274
R2 = 0.9923
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Appendix B: Normalizing Kinetic Data (continued) 
 
Step 3: Use the slope of the line and y-intercept to determine total protein concentration 
in sample.  
 
Results: 
Sample Abs Abs Avg Abs
Calculated 
Concentration (ug/ml)
Conc 
(mg/ml)
TEV Positive Control 0.7045 0.6649 0.6847 4286.9 4.29
RS-TEV Off 0.7831 0.8277 0.8054 5215.4 5.22
RS-TEV On 0.7985 0.7230 0.7608 4871.9 4.87  
 
 
Step 4: Calculate total protein concentration per sample.  To equalize protein 
concentrations between treatments, use a ratio of protein concentration of sample ÷ 
protein concentration of control, then multiply ratio by emission ratio of sample. 
For example: 
 
RS-TEV Off RS-TEV Off Emission Ratio 
TEV Positive Control
                                                                         Normalized RS-TEV Off Emission Ratio
 
⎛ ⎞∗⎜ ⎟⎝ ⎠
=
 
Sample emission ratio data: 
raw data 1.3685 1.3817
RS-TEV Off 
 
 
( )5.22       1.368 1.665
4.29
⎛ ⎞∗ =⎜ ⎟⎝ ⎠  
 
Sample Normalized emission ratio data: 
raw data 1.3685 1.3817
normalized 1.6652 1.6812
RS-TEV Off 
 
 
 
 
Step 5: Plot and analyze normalized data. 
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